Patent Grant
9084566
The parenteral administration (by which is meant administration in a manner other than through the digestive tract, such as by intravenous or intramuscular injection or inhalation) of beneficial agents and fluids is an established clinical practice. Parenteral administration of beneficial agents is an effective remedy for many patients when administered properly and according to instructions. However, studies have shown that, on average, about 10% of patients receive an incorrect injectable medication. For example, a significant percentage of serious errors are associated with the administration of intravenous (IV) medication.
A patient's response to drugs delivered intravenously is rapid because the gastrointestinal system is bypassed. Thus, if an error is made, there is little time to compensate. Most critical drugs are delivered intravenously. Correct administration is a process that often involves several individuals for delivering an accurate dose of a drug to a particular patient at a prescribed time and through a particular administration route. It is not difficult to comprehend the potential for error, as well as the undesirable probability that the occurrence of an error can result in one or more detrimental effects to the patient.
An intravenous error may be induced at any time throughout the process of ordering, transcribing, dispensing, and administering a drug. For example, an ordering error may occur because an order is illegible, incomplete, or entered on the wrong patient's chart, because a decimal is misplaced or inappropriate, or unacceptable prescription abbreviations are used, or because an inappropriate drug is selected or a patient's allergies are not properly identified. Transcription errors may occur because an order was not transcribed, not completely signed off, or incorrectly transcribed onto the Medication Administration Record (MAR). Also, on occasion a patient's allergies are not transcribed or a transcription is illegible. Dispensing errors may occur with respect to the dose, or the identification of the medication or patient. An administration error may occur at any time during the course of a patient's care and may concern the patient or drug identification, or the time, dose, or route of drug administration. It is notable that research indicates that 60-80% of intravenous errors are attributed to humans.
It follows then that one way to reduce the potential for error is to automate as much as possible the process of drug ordering, transcribing, dispensing, and administering.
Information technology may be utilized for automating portions of the drug ordering, transcribing, dispensing, and administration process. For example, the potential for error may be reduced by cross referencing infusion data used to program a pump, by reviewing data programmed into a pump prior to enabling the pump to operate, and/or by detecting if programmed data is changed.
Several systems have been developed in an attempt to reduce the above described errors. Examples of such systems are disclosed in U.S. Pat. Nos. 5,781,442; 5,317,506 and 6,985,870.
Despite the presence of these and other systems, there continues to be a need for improved systems. For example, it would be an important advancement in the art if a parenteral administration system could be developed that provided for a prospective definitive confirmation of a patient being properly matched with a dosage without the need for any human intervention. Also of interest would be the development of a system which provides for a definitive record of whether the proper beneficial agent and amount has been administered, and whether the medication has been administered at the proper time, again without the need for any human intervention. These advantages are available through the present smart parenteral delivery invention.
The inventive systems and methods of use described herein provide, for the first time, accurate evaluation of a fluid transfer event between a fluid delivery device and a patient. The evaluation can be prospective, such that the evaluation provides beforehand knowledge about a future or contemplated fluid transfer event, i.e., an event that has not yet occurred. For example, the evaluation made possible by embodiments of the systems and methods of the invention provides prospective knowledge that a patient is properly matched to a future fluid delivery event from a parenteral fluid deliver device. The evaluation can also be historic, such that the evaluation provides knowledge about a fluid transfer event that has already occurred. In addition, the inventive smart parenteral administration system provides definitive, automatic, and specific identification and detection of parenteral administration of fluids, e.g., fluids that include beneficial agents, to a patient from a parenteral fluid transfer device. In yet other embodiments, the evaluation is real-time, such that that the evaluation provides knowledge about the fluid transfer event as it is occurring.
Specific prospective, real-time and/or historical identification and detection of a parenteral fluid transfer event is achieved with an intelligent fluid delivery system. Embodiments of the invention include an intelligent fluid delivery system which includes a patient associated identifier and a parenteral fluid delivery device (such as a syringe, intravenous administration device, inhaler, or dialysis device, as reviewed in greater detail below). The delivery device and identifier are configured so that a fluid transfer signal can be transmitted between them using the patient's body as a communication medium. By using the patient's body as a communication medium for the fluid transfer signal, prospective, real-time and/or historical definitive knowledge about a prospective and/or actual fluid transfer event of fluid between the delivery device and the patient is automatically obtained. Since the knowledge is automatically obtained, no human intervention is required to obtain the knowledge. Instead, without any human intervention, the system obtains the knowledge and provides it to a user for use, e.g., by outputting data comprising the knowledge to a user and/or recording the data to a suitable recording medium, such as a computer readable medium. Furthermore, the knowledge about the fluid delivery event is definitive, such that one can know for sure that the knowledge is about the specific patient and the specific fluid delivery device of interest, again without the requirements of any human intervention or verification.
The content of the fluid transfer signal may vary widely depending on a number of factors, including but not limited to: the direction of the fluid transfer signal (for example whether it travels from the patient associated identifier to the fluid delivery device and/or from the fluid delivery device to the patient associated identifier); the configuration of the system, e.g., whether the patient associated identifier broadcasts simple patient identification information or more complex patient information, such as health history information, one or more physiological parameters, etc.; whether additional components are present in the system, e.g., a hospital information system, signal relay devices, etc.; whether the purpose of the system is to provide for prospective and/or historical administration data, etc.; and the like.
As indicated above, in certain embodiments the fluid transfer signal is one that is employed in prospective applications. Prospective applications of the invention are those applications where the system is employed to automatically confirm that an intended fluid transfer event is correct for a given patient. For example, a prospective application is one where the fluid transfer signal provides information that a fluid connection has been established between the fluid delivery device and the patient and that the device is ready to transfer fluid to the patient. In yet other embodiments, the fluid transfer signal is one that is employed in historical applications. Historical applications as described herein include retrospective applications, e.g., where the knowledge is employed after the fluid transfer event has occurred, for example in determining an accurate medication history for the patient, etc. For example, the fluid transfer signal in embodiments of such applications is one that provides for actual knowledge that fluid has been parenterally transferred from the device to the patient. In yet other embodiments, the fluid transfer signal is one that is employed in real-time applications, e.g., where the knowledge is employed as the fluid is being transferred between the delivery device and the patient.
Embodiments of the invention include delivery devices that are configured to transmit the fluid transfer signal only when fluid is delivered from the device to the patient and in a manner such that transmission can only occur when the device actually contacts the patient and fluid is transferred to the patient.
As reviewed above, the content of the fluid transfer signal may vary greatly. With respect to prospective applications, the fluid transfer signal may provide for simple identification data, or more complex data such as patient history, prescription information, etc. For historical applications, the fluid transfer signal may be qualitative, e.g., provide a simple yes or no indication of whether transfer has occurred, or quantitative, e.g., provide more detailed information about the fluid transfer, such as the amount of fluid transferred, etc.
The above and additional embodiments of the inventive system are now described in greater detail below.
As summarized above, the invention provides methods and systems for evaluating a fluid transfer event between a parenteral fluid delivery device and a patient. The evaluation of the fluid transfer event can be prospective, real-time and/or historic, as desired, and take a variety of different formats. For example, prospective evaluation of a fluid transfer event includes situations where a determination is made of whether a given transfer event is properly matched to a given patient, and may further include subsequent action based on the determination, e.g., initiation of fluid transfer from the device to the patient if a proper match is determined, sounding of an alarm and/or inhibition of fluid transfer if a proper match is not determined, etc. Real-time evaluation of a fluid transfer event includes situations where a determination is made as to whether a given fluid transfer event should be continued once initiated, e.g., based on received physiological parameters from the patient, a determination of what fluids were actually administered to a patient, including when, etc. Historic evaluation includes situations where knowledge regarding actual fluid transfer events that have occurred is employed, e.g., in developing a true patient medication history, etc.
In further describing various aspects of the invention, general aspects of the inventive systems and methods are reviewed first in greater detail, and then in view of specific embodiments.
Aspects of the invention include smart parenteral fluid delivery systems that provide, for the first time, a truly accurate and automated evaluation of a fluid transfer event, whether the evaluation may be prospective, real-time or retrospective. The system is smart in that no human intervention is required for the evaluation. Furthermore, the system as a whole includes processing capability that is configured to receive one or more inputs (for example in the form of fluid transfer signals) and process the input(s) to make an evaluation about a given fluid transfer event.
Embodiments of systems of the invention include a parenteral fluid delivery device and a patient associated identifier. The parenteral fluid delivery device and the patient associated identifier are configured so that a fluid transfer signal can be transmitted between the two components using the body of the patient as a communication medium. To employ the body as a communication medium for the fluid transfer signal, a fluid communication between the fluid delivery device and the patient is first established. As the body of the patient is used as a communication medium, the signal that is transferred between the parenteral fluid delivery device and the patient travels through the body, (for example in a direction from the patient associated identifier to the delivery device and/or from the delivery device to the patient associated identifier), and requires the body as the conduction medium. In certain embodiments, the fluid transfer signal is conductively transmitted between the fluid delivery device and the patient associated identifier using the patient as a conductive medium.
As the body is required as a conduction medium and requires the establishment of fluid transfer connection between the fluid delivery device and the patient, receipt of the signal (either at the patient associated identifier, the parenteral fluid delivery device or another component of the system, such as reviewed in greater detail below) provides accurate knowledge upon which an evaluation of a fluid transfer event may be made. This accurate knowledge can then be further employed in a variety of different ways, depending on the application, where such applications include prospective, real-time and historic applications. Examples of prospective applications are those in which the fluid transfer signal is employed to determine beforehand one or more aspects about a contemplated or future fluid delivery event between the fluid delivery device and the patient, such as whether the type and/or dosage of a fluid is appropriate for the patient. Examples of historic or retrospective applications of the methods and systems of the invention include applications where the fluid transfer signal is employed to obtain an accurate history of a fluid(s) that has been delivered to a patient via a parenteral fluid delivery device.
As summarized above, a component of the systems of the invention is a patient associated identifier. The patient associated identifier is a device that is configured to be associated with the patient, for example either topically or implanted, and includes a communications element that performs at least one of broadcasting and receiving functions. The patient associated identifier is one that at least provides identifying information about the patient. The identifier can be configured in a variety of different ways, including formats that are configured to simply broadcast identifying information about the patient (where the patient associated identifier may only include a broadcasting element) to more complex formats where the identifier receives information about a fluid transfer event (such as where the patient associated identifier includes a receiver element) and internally processes that information to evaluate the fluid transfer event in some manner. As such, in certain embodiments the identifiers are configured to simply broadcast identifying information about the patient to the fluid delivery device. In such embodiments, the identifiers are signal receivers that are configured to receive a signal from a parenteral fluid delivery device enabled to transmit a fluid transfer signal. Patient associated identifiers of interest include, but are not limited to, those described in: PCT/US2006/16370 titled “Pharma-Informatics System” and filed on Apr. 28, 2006; as well as U.S. Provisional Application Ser. No. 60/887,780 titled “Signal Receivers for Pharma-Informatics Systems” filed on Feb. 1, 2007; the disclosures of which are herein incorporated by reference.
In certain embodiments, the patient associated identifier is one that is sized to be stably associated with a living subject in a manner that does not substantially impact movement of the living subject. As such, the patient associated identifier has dimensions that, when employed with a subject, such as a human subject, will not cause the subject to experience any difference in its ability to move. As such, the patient associated identifier is dimensioned such that its size does not hinder the ability of the subject to physical move. In certain embodiments, the patient associated identifier has a small size; where in certain embodiments the patient associated identifier occupies a volume of space of about 5 cm3 or less, such as about 3 cm3 or less, including about 1 cm3 or less.
The patient associated identifiers of interest include both external and implantable devices. In external embodiments, the patient associated identifier is ex vivo, by which is meant that the patient associated identifier is present outside of the body during use. Where the identifiers (for example signal broadcasters and/or receivers) are external, they may be configured in any convenient manner, where in certain embodiments they are configured to be associated with a desirable skin location. As such, in certain embodiments the external patient associated identifiers are configured to be contacted with a topical skin location of a subject. Configurations of interest include, but are not limited to: patches, wrist bands, belts, etc. For instance, a watch or belt worn externally and equipped with suitable receiving electrodes can be used as signal receivers in accordance with one embodiment of the present invention. The patient associated identifiers may provide a further communication path via which collected data can be extracted by a patient or health care practitioner. For instance, an implanted collector may include conventional RF circuitry (operating for example in the 405-MHz medical device band) with which a practitioner can communicate, e.g., using a data retrieval device, such as a wand as is known in the art. Where the patient associated identifier includes an external component, that component may have output devices for providing feedback, e.g., audio and/or visual feedback; examples of which include audible alarms, LEDs, display screens, or the like. The external component may also include an interface port via which the component can be connected to a computer for reading out data stored therein. By further example, the patient associated identifier could be positioned by a harness that is worn outside the body and has one or more electrodes that attach to the skin at different locations. The inventive construct can be linked to a portable device, for example a watch that has one or two electrodes dispersed on the wrist. There are many places where such a receiving electrode system could be placed and created such as on hearing aids that beep, a necklace, a belt, shoes (PZT-powered), eyeglasses, or earrings. In these external embodiments, a portion of the patient associated identifier, e.g., electrode, contacts the skin in a manner such that a communication line (such as a conductive communication line) that includes the patient's body may be established between the identifier and a fluid delivery device during use of the system.
In certain embodiments, the external patient associated identifier includes miniaturized electronics which are integrated with the electrodes to form an adhesive bandage style patch (e.g. a BANDAID™ style patch) with electrodes that, when applied, contact the skin. This configuration may further include a battery. The adhesive bandage style patch may be configured to be positioned on a desirable target skin site of the subject, e.g., on the chest, back, side of the torso, etc. In these embodiments, the circuitry of the patch may be configured to receive signals from devices inside of the subject, e.g., from an identifier of a pharma-informatics enabled pharmaceutical composition, and then relay this information to an external processing device, e.g., a PDA, smartphone, etc. Adhesive bandage style devices that may be readily adapted for use in the present systems include, but are not limited to: those described in U.S. Pat. No. 6,315,719 and the like.
In certain embodiments, the patient associated identifier (e.g., signal broadcaster and/or receiver) is an implantable component. By implantable is meant that the signal receiver is designed, i.e., configured, for implantation into a patient, e.g., on a semi-permanent or permanent basis. In these embodiments, the signal receiver is in vivo during use. By implantable is meant that the patient associated identifiers are configured to maintain functionality when present in a physiological environment, including a high salt, high humidity environment found inside of a body, for two or more days, such as about one week or longer, about four weeks or longer, about six months or longer, about one year or longer, e.g., about five years or longer. In certain embodiments, the implantable circuits are configured to maintain functionality when implanted at a physiological site for a period ranging from about one to about eighty years or longer, such as from about five to about seventy years or longer, and including for a period ranging from about ten to about fifty years or longer.
For implantable embodiments, the identifiers may have any convenient shape, including but not limited to: capsule-shaped, disc-shaped, etc. One way to achieve the small size is by including a rechargeable battery. Because this is not a life-support device, but rather a sensing and/or information transmission device, embodiments of the device have a natural life of two weeks, and recharge automatically off of coils in the patient's bed so that the device may be constantly recharging. The patient associated identifier may be configured to be placed in a number of different locations, e.g., the abdomen, small of the back, shoulder (e.g., where implantable pulse generators are placed) etc.
In addition to being configured to participate in transmission of a signal between the patient associated identifier and a fluid delivery device using the patient's body as a conduction medium, the patient associated identifier may further include one or more distinct physiological parameter sensing abilities. By physiological parameter sensing ability is meant a capability of sensing a physiological parameter or biomarker, such as, but not limited to: heart rate, respiration rate, temperature, pressure, chemical composition of fluid, e.g., analyte detection in blood, fluid state, blood flow rate, accelerometer motion data, IEGM (intra cardiac electrogram) data, etc. Where the patient associated identifier has physiological parameter or biomarker sensing capability, the number of distinct parameters or biomarkers that the signal receiver may sense may vary, e.g., one or more, two or more, three or more, four or more, five or more, ten or more, etc. The term “biomarker” refers to an anatomic, physiologic, biochemical, or molecular parameter associated with the presence and severity of specific disease states. Biomarkers are detectable and measurable by a variety of methods including physical examination, laboratory assays and medical imaging. Depending on the particular embodiment, the signal receiver may accomplish one or more of these sensing functions using the signal receiving element, e.g., using electrodes of the receiver for signal receiving and sensing applications, or the signal receiver may include one or more distinct sensing elements that are different from the signal receiving element. The number of distinct sensing elements that may be present on (or at least coupled to) the signal receiver may vary, and may be one or more, two or more, three or more, four or more, five or more, ten or more, etc.
The patient associated identifier may have any convenient power source, which could either be a primary cell or rechargeable battery, or one that is powered by broadcasting inductively to a coil, or even a photoelectric or other power source, as may be appropriate for the identifier given its site of association with the patient (such as topical or internal) and expected operating conditions.
The parenteral fluid delivery device is a device that delivers a quantity of a fluid (such as a gas or liquid) to a patient by a route other than the digestive tract, e.g., via a pulmonary route, via intramuscular injection, via intravenous delivery, etc. For purposes of describing the present invention, pulmonary administration is considered to be parenteral administration because delivery is via the lungs, even though entry to the lungs is via the mouth and/or nasal passages. As such, parenteral fluid delivery devices include syringes, intravenous systems, infusion pumps, dialysis systems, ventilators, anesthesia machines, nebulizers/inhalers, etc. The delivery device will include a fluid transfer signal generator, e.g., in the form of an integrated circuit or other suitable structure, that transmits a signal to a receiver upon transfer of fluid to the patient. In certain situations, the parenteral fluid delivery device is one that provides for one way transfer of fluid from the device to the patient. Examples of such devices are syringes, intravenous delivery devices and inhalers. In certain situations, the parenteral fluid delivery device provides for removal of fluid from a patient and the delivery of fluid to the patient. An example of such a device is a dialysis device.
One type of fluid that may be transferred to the patient is a liquid. The liquid may vary greatly in composition, and may include one or more distinct beneficial agents in a liquid pharmaceutically acceptable vehicle, e.g., one or more pharmaceutical agents, or may be a beneficial agent in its own right, e.g., such as where the liquid is a plasma volume expander.
For parenteral delivery of a liquid, the delivery device may vary. One type of device of interest is a syringe or analogous structure, e.g., that is configured for intramuscular injection of the liquid. Also of interest are intravenous administration devices, which may include a liquid storage element, e.g., a fluid containment or IV bag, a fluid metering unit or pump, a drip bag, etc. Another type of fluid transfer event that may be monitored by the systems of the invention is where fluid, e.g., blood, dialysate, etc., is transferred from a patient to an external device and then transferred back from the device to the patient, typically after some type of processing in the device. An example of a parenteral fluid delivery device that finds use in these situations is a dialysis machine, where such devices may be parenteral dialysis devices or hemodialysis devices, etc. Another type of fluid of interest is a gas. A variety of different beneficial agents are delivered in aerosolized format (which is a type of gas) to patients, where devices configured for such delivery are generally referred to as inhalers. As such, embodiments of parenteral delivery devices of the invention are inhalers.
A given fluid delivery device may include a single component or two or more disparate components (such as syringes and vials, fluid containment bags and IV pumps, etc.) which are operatively connected to one another during use and collectively comprise the ability to transfer a fluid transfer signal between the device and a patient associated identifier, as reviewed above. As such, the various components of the systems may further include communication elements, e.g., broadcasters and/or receivers, as may be required or desired for a given embodiment of the system. Such components may further include power sources, as may be desired, where any convenient power source may be present, including those mentioned above in connection with the patient associated identifier.
Embodiments of the fluid delivery devices may include what is viewed as pharma-informatics enabled components, such as pharma-informatics enabled fluid containers. By pharma-informatics enabled fluid container is meant a fluid container, e.g., bag, vial, etc., that includes a volume of fluid that is to be transferred to a patient, e.g., via the fluid delivery device, where the container also has associated with it some identifier that provides identifying information about the contents of the container. The nature of the identifying information may vary greatly, from the simple, e.g., the name of the fluid, the name of the pharmaceutical agent present therein, to the more complex, e.g., the dosage present in the container, the history of the fluid in the container, the quality of the fluid in the container (e.g., whether it is compromised or spoiled), etc. The nature of the identifier may also vary, e.g., from being a passive interrogatable element, such as a barcode or other machine readable identifier, to a more active component, such as a component that can broadcast information and includes a power source. Sensors, as described below, may also be associated with the medical containers.
Where a given system includes two or more different fluid containers, the system may be configured as a multiplex system. Embodiments of the multiplex system are configured to sufficiently reduce or eliminate cross-talk and confusion between various broadcast signals of multiple components of the multiplex system such that a given fluid transfer signal about a given fluid and a patient may be properly matched up or associated with each other. For example, a signal generated about a first IV bag may be distinguishable from a signal generated about a second bag, where distinguishable signals may be provided in a number of different ways, e.g., by using an appropriate time-based communication protocol, by having signals of different frequencies, etc. Of interest are the signal protocols described in PCT/US2006/016370 filed on Apr. 28, 2006, the disclosure of which is herein incorporated by reference. In certain embodiments where multiple different fluid containers are present in a given fluid delivery system, the different fluids may be color coded to provide an additional distinguishing feature, where this color coding may be detected and transmitted to the patient associated identifier (for example as part of a fluid transfer signal) for further confirmation that the right medicine is being delivered to the right patient.
In certain embodiments, a given fluid delivery system may include both a pharmacological agent and an amount of an “antidote” for that agent should the system identify, e.g., through physiological sensing during delivery, such as may occur during real-time applications, that the patient is adversely reacting to the pharmacological agent. In such embodiments, delivery of the agent may be automatically stopped, and delivery of the antidote may be automatically commenced, as automatically directed by the system without any human intervention.
As detailed below, certain embodiments are characterized in that the patient associated identifier and/or the fluid delivery device further transmits a signal to and/or receives a signal from an additional external component. The external component is, in certain embodiments, an external processing component, such that it is designed to accept data, perform prescribed mathematical and/or logical operations, and output the results of these operations. Examples of external components of interest include, but are not limited to: a healthcare provider network (such as a hospital information system (HIS); a home healthcare information system, etc). Accordingly, systems of the invention may further include an external processor component, such as a HIS or analogous system that includes various aspects of a patient specific data, such as prescriptions, treatment regimens, health history, dosage guidelines, etc. This data may include information obtained from an electronic medication storage unit, e.g., a PYXIS™ storage unit, etc.
The systems may further include various sensors. Physiological sensors may be associated with the patient, and may or may not be part of the patient associated identifier. Physiological sensors of interest include, but are not limited to: heart rate sensors, breathing sensors, temperature sensors, etc., as described more fully above in connection with the patient associated identifier.
Sensors may also be associated with various components of the fluid delivery system. Sensors may be associated with fluid containers, e.g., to detect a color-coded liquid therein, to detect clarity of a fluid, to detect the presence of one or more analytes in the fluid, etc. Sensors may also be present in tubing components of the system, e.g., to detect proxies of bacterial infection, such as turbidity, etc.
As reviewed above, the system is configured to transfer a fluid transfer signal between the patient associated identifier and the fluid delivery device, where the signal is transferred between these two components using the patient's body as a signal conduction medium. The physical nature of the signal may vary, e.g., where physical types of signals of interest include electric, magnetic, optical, thermal, acoustic, etc. Because the fluid transfer signal is transferred between the two components using the patient's body as a conduction medium, fluid communication is established between the parenteral fluid delivery device and the patient prior to transmission of the fluid transfer signal.
The content of the fluid transfer signal may vary depending on the particular application in which the methods and systems are employed, where the content may range from simple to complex, depending on the particular type of application, e.g., prospective, real-time or historical, the direction, e.g., to and/or from the patient associated identifier, etc. A given fluid transfer signal provides prospective information about a fluid transfer event if the fluid transfer event is a future fluid transfer event, i.e., the fluid transfer event has not yet occurred. A given fluid transfer signal provides real-time information about a fluid transfer event if the fluid transfer event is a currently occurring fluid transfer event, i.e., the fluid transfer is currently happening. A given fluid transfer signal provides retrospective information about a fluid transfer event if the fluid transfer event is a past fluid transfer event, i.e., the fluid transfer event has already occurred.
In certain embodiments, the content of the fluid transfer signal is that a fluid connection has been established between the fluid delivery device (including disparate components thereof) and the patient. In certain embodiments, the content of the fluid transfer signal is that a previously established fluid connection between the fluid delivery device (including disparate components thereof) and the patient has been interrupted. In addition to an indication that a fluid connection has been established, the fluid transfer signal may include additional content, e.g., where additional content of interest includes, but is not limited to: patient specific content, fluid specific content, delivery device specific content, etc.
Patient specific content of interest includes, but is not limited to: identity of patient (such as name, unique identifier), general information about the patient, e.g., gender, age, race, etc., health history of patient, health status of patient, including one or more sensed physiological parameters, which may or may not be combined into a health indicative marker, e.g., a wellness marker or index, and the like.
Fluid specific content of interest includes, but is not limited to: identity of the fluid, the contents of the fluid, the identity of one or more pharmacological agents in the fluid, the concentrations of such agents in the fluid, the history of the fluid, e.g., where manufactured, how stored, the quality of the fluid, e.g., whether compromised or not, etc. Also of interest is fluid container specific content, which content includes, but is not limited to: the source/history of the container, the identity of the container, e.g., general (e.g., type, such as bag) or specific (e.g., serial no.), etc.
Device specific content of interest includes, but is not limited to: the state of the device (for example whether the device on or off), the settings of the device, e.g., flow rates, the source/history of the device, etc.
In certain embodiments, the fluid transfer signal includes information that an actual fluid transfer event has occurred between a parenteral fluid delivery device and a patient. In such embodiments, the fluid transfer signal provides information about whether fluid has been transferred between the parenteral delivery device and the patient. The fluid transfer signal is one that provides for actual knowledge that fluid has been parenterally transferred from the device to the patient.
Embodiments of the invention include delivery devices that are configured to transmit the fluid transfer signal only when fluid is delivered from the device to the patient and in a manner such that transmission of the signal can only occur when the device actually contacts the patient and fluid is transferred to the patient. As such, the system is distinguished from other systems which provide for generation of a signal when a package is opened, or other proxy-type signals for actual administration of the fluid. Instead, the system of the invention provides a signal that provides knowledge that delivery of the fluid to the patient actually occurred, e.g., by only transmitting the signal when the device touches the patient and fluid enters the patient from the device. While the fluid transfer signal may be transmitted between the parenteral fluid delivery device and the patient associated identifier using any convenient protocol, in certain embodiments protocols that ensure transmission only occurs upon contact of the device with the patient are employed. One such protocol of interest is conductive transmission, e.g., where the body is employed as a conductive medium between the fluid delivery device and the patient associated identifier to provide for transmission of the signal. Accordingly, a given fluid transfer signal may include qualitative or quantitative information. Qualitative information is information that is not tied to specific numerical values or units, and includes but is not limited to: identifying information, quality control information about a fluid (for example age, storage conditions, etc.), information about a patient, e.g., how patient is responding, etc., whether something is or is not present, etc. Quantitative information is information that includes numerical values or units, and includes but is not limited to dosage information, etc.
As reviewed above, communication of the fluid transfer signal between the patient associated identifier and the fluid delivery device employs the patient's body as a conductive medium. One or more additional and separate communication lines may be established between various components of the system, such as between the patient associated identifier and an external component, such as a hospital information system, between components of a fluid delivery device, such as an infusion pump and a fluid container, between the fluid delivery device and the hospital information system, etc. These additional communication lines may be wired or wireless communication lines, as desired, employing traditional physical connections, such as wires, optical fibers, etc., or wireless communication protocols, e.g., RFID, etc. These additional communication lines may be employed to transfer information and/or power between the different device components. For example, disparate components of a fluid delivery system may include communications components that are powered via wireless transmission of power from one element to another. These additional communication lines are, in certain embodiments, non-conductive communication lines.
As indicated above, certain applications of the systems are prospective applications, in that the system is employed prospectively to evaluate a fluid transfer event (such as delivery of a fluid dosage to a patient), where the fluid transfer event has yet to actually occur. Such applications include situations where the system is employed as a check to ensure that a given dosage of a fluid is properly matched with a patient. In addition to this simple check, the system can also ensure that the dosage to be delivered is appropriate. If a proper match is detected between the patient and the fluid transfer event of interest, the system can be configured to automatically enable the fluid transfer event to occur, e.g., by activating the fluid delivery device, such as the pump. Alternatively, where a proper match between a patient and a given fluid transfer event is not detected, the system can be configured to disable the fluid transfer event, e.g., by inactivating the fluid delivery device, etc. Where desired, the systems of the invention are configured to provide an error signal upon detection of an error in a parenteral administration event. The detected error may vary greatly, and examples include situations where the patient associated identifier has knowledge of medicines that should not be administered to the patient and the identity of a medicine is transmitted to the receiver. In addition, the system may be configured to provide tight control over administration of what are known in the art as “high-alert medications,” such that the system is configured to only enable administration of such medications in predetermined dosage ranges and provides error signal upon deviation from such ranges. Accordingly, the system finds use with what are known in the art as “high-alert” medications.” Classes/Categories of such medications are: adrenergic agonists, IV (such as epinephrine); adrenergic antagonists, IV (such as propranolol); anesthetic agents, general, inhaled and IV (such as propofol); cardioplegic solutions; chemotherapeutic agents, parenteral and oral; dextrose, hypertonic, 20% or greater; dialysis solutions, peritoneal and hemodialysis; epidural or intrathecal medications; glycoprotein IIb/IIIa inhibitors (such as eptifibatide); hypoglycemics, oral; inotropic medications, IV (such as digoxin, milrinone); liposomal forms of drugs (such as liposomal amphotericin B); moderate sedation agents, IV (such as midazolam); moderate sedation agents, oral, for children (such as chloral hydrate); narcotics/opiates, IV and oral (including liquid concentrates; immediate- and sustained-release formulations); neuromuscular blocking agents (such as succinylcholine); radiocontrast agents, IV; thrombolytics/fibrinolytics, IV (such as tenecteplase); and total parenteral nutrition solutions. Specific “high-alert medications” include: amiodarone, IV; colchicine injection; heparin, low molecular weight, injection; heparin, unfractionated, IV; insulin, subcutaneous and IV; lidocaine, IV; magnesium sulfate, injection; methotrexate; nesiritide; nitroprusside sodium, injection; potassium chloride concentrate, injection; potassium phosphates, injection; sodium chloride injection, hypertonic (more than 0.9% concentration); and warfarin. The signal may also vary greatly, including an audible alarm, an alarm signal sent to a physician, etc. Such embodiments include methods where the system is monitored for the occurrence of the error signal.
In such applications, a processor is conveniently employed to match patient specific information and fluid transfer event specific information, e.g., to determine whether or not to allow the fluid transfer event to occur, to produce an error signal, etc. The location of this processor may vary within the components of the system, as desired. As such, in certain embodiments, the processor may be located in the patient associated identifier. In certain other embodiments, the processor may be located in the fluid delivery device. In yet other embodiments, the processor may be located in the hospital information system.
As indicated above, certain applications of the systems are real-time applications, in that the system is employed to evaluate a fluid transfer event (such as delivery of a fluid dosage to a patient) while the fluid transfer event is actually occurring, i.e., is in progress. For example, the system can be used to monitor the patient for an adverse reaction during delivery of the fluid, e.g., by monitoring physiological parameters of the patient. If monitored physiological parameters vary from acceptable predetermined ranges, the system can be configured to produce an error signal, e.g., as described above, and or take action, e.g., stop delivery of the medication, administer an antidote, etc.
Also of interest are uses of the systems and methods for historical applications, such that the systems are employed to obtain a true and correct record of fluid transfer events that have actually occurred between a patient and a fluid delivery device. Historical applications are any applications that use information which includes knowledge that a fluid transfer event has actually occurred. Where desired, the systems of the invention are configured to provide an error signal upon detection of an error in a parenteral administration event. One example of such an application is where, during a given fluid transfer event, the transfer of fluid is interrupted. The system may be configured to generate a signal indicative of such an interruption, which could be manifested as an alarm, etc. The detected error may vary greatly, and examples include situations where the receiver has knowledge of medicines that should not be administered to the patient and the identity of a medicine is transmitted to the receiver. Another example of an administration error that may be detected includes situations where the receiver can detect the occurrence of an adverse reaction, e.g., by monitoring physiological parameters of the patient. The signal may also vary greatly, including an audible alarm, an alarm signal sent to a physician, etc. Such embodiments include methods where the system is monitored for the occurrence of the error signal.
True and accurate records of fluid transfer events also find use in providing health care practitioners or other individuals with accurate treatment records for a given patient. As such, historical applications include employing the fluid transfer event data in further treatment of an individual, e.g., developing future treatment regimens and/or modifying existing treatment regiments.
Additional historical applications of interest include employing the fluid transfer event data for invoicing purposes, e.g., so that patients are accurately, billed for medications and/or services that they actually receive, etc.
Aspects of the invention having been described in general terms above, additional details in the context of specific embodiments are now provided.
Embodiments of the smart therapeutics system can include a beneficial agent with a chip. The chip can contain information about the type of beneficial agent to be administered to the patient. Upon extracting the beneficial agent from the holding container, e.g., a vial, a signal can be sent from the vial to a chip within the syringe. The broadcasted signal can indicate the type of beneficial agent extracted from the vial. Upon injection into the patient, the information can be sent from the syringe to an information management database located in, on, or near the patient, e.g., the patient associated identifier. The system can also notify the receiver about any therapies the patient is undergoing, such as dialysis. In this case, the dialysis machine, or an add-on module added to current dialysis machines, can be used to collect and transmit data about the dialysis being performed and parameters of the blood going out of and in to the patient during dialysis. Upon successful detection and decoding of the transmitted signal, the receiver can activate an alert to let the nurse or other attending person and/or the patient that the receiver has successfully received information about the medication or therapy which was administered.
In one embodiment of the present invention,
In certain embodiments, when syringe 1 enters vial 5, chip 7 within vial 5 begins to broadcast the name of the medicine or a number that encodes the medicine. Chip 3 within syringe 1 begins to “listen” for the signal broadcasted by chip 7 when fluid enters into syringe 1. Chip 3 located in syringe 1 can record the broadcasted signal.
In one embodiment of the present invention, when the medicine is injected into the patient (such that fluid is transferred to the patient from the device), chip 3 in syringe 1 broadcasts the encoded number through syringe 1. For example, the broadcasting embodiment may be a coaxial transmitter with two conductors transmitting the encoded number into the patient. The encoded number may be picked up by a receiver located in, on, or around the patient. The encoded number is an example of a qualitative fluid transfer signal.
In an additional embodiment of the present invention, the broadcasting embodiment can also be a coil embedded in syringe 1 with one or more wires attached to chip 3. The power source can also have a coil on it. The fluid going into syringe 1 can activate the power source in syringe 1. The activated power source can energize the coil on the power source. The coil on the power source can electrically conduct with the coil attached to chip 3, essentially acting as an RFID interface. Activating the power source is not limited to electrical conduction but could be accomplished through other techniques, for example, proximity conduction. In this manner, a fluid transfer signal that is dependent on actual injection of fluid is transmitted.
In an additional embodiment of the present invention, multiple modes of communication between the broadcasting unit in syringe 1 and the receiving unit located on the patient are possible. For example, communication between the broadcasting unit in syringe 1 and the receiving unit located on the patient can be accomplished through conduction patterns, a RF type of coil system or an antenna system.
There are several methods available to identify the type of beneficial agent in vial 5. In one embodiment of the present invention, the beneficial agent can be identified by detecting change in impedance, inductance, or capacitance of the beneficial agent as it is drawn into syringe 1. This change can be encoded in chip 7 and transferred to chip 3. When chip 3 receives the encoded signal, the broadcasting embodiment in syringe 1 begins broadcasting to the receiving unit located in, on or around the patient.
In one embodiment of the present invention, syringe 1 can contain chip 3 and each chip 3 may be identical. For example, chip 3 within syringe 1 may only contain a writable receiving unit. Chip 3 in syringe 1 receives and stores the encoded signal from chip 7 in vial 5. Chip 3 in syringe 1 relays the encoded signal to the broadcasting unit in syringe 1. The broadcasted signal is picked up by a receiver in, on, or around the body. As used herein the term “chip” means processing element, e.g., and may be an integrate circuit (IC).
On the other hand, chip 7 in vial 5 may be unique. For example, each chip may broadcast a different encoded signal depending on the contents of the vial.
In another embodiment of the smart parenteral delivery system, the encoded data is stored in, on, or around the patient. By having the receive unit in, on, or around the patient, the receive computer can be the hub for the information management system.
Consequently, no other receive units are required. For example, a smart parenteral receive system may consist of any syringe and vial containing send and receive chips and a receive unit (such as a patient associated identifier) associated with the patient, e.g., located in, on, or around the patient. Prior inventions include procedures that require manual input of data such as the scanning of bar codes and manual recording of the amount and time when the medicine was administered. Such steps are not required in these embodiments of the present invention.
In an additional embodiment of the present invention, the smart therapeutics system can record how much fluid is withdrawn from the vial and ultimately delivered to the patient. In certain embodiments this includes having a coil that is fixed at one end of the syringe and then another coil that rests on the plunger. As the plunger is pushed, the mutual inductance between the two coils changes and the position over time of the plunger can be determined. In another embodiment of the invention, two conductive strips are embedded into the vial wall and a conductor on the plunger. As the plunger is pressed, the impedance between the two strips on the vial wall change as the conductive strips capacitively couple between the conductors on the plunger. The impedance can be measured and the amount of fluid withdrawn can be determined. In another embodiment of the invention, a direct impedance measurement of the fluid is performed to determine the amount of fluid withdrawn. Similarly, a capacitive measurement of the plunger versus the plate at the bottom of the system is used in certain embodiments to determine the amount of fluid withdrawn. The above discussion provides examples of quantitative fluid transfer signals.
In an additional embodiment of the system, a light or some other type of indicator, e.g. a green light, flashes when the encoded signal is delivered to the patient's receive system (patient associated identifier) from the broadcasting chip. This alerts the administrator to withdraw the syringe from the patient. The indicator would alert the administrator that the encoded signal has been sent and the medicine has successfully been delivered.
A schematic diagram of a smart fluid delivery system according to an embodiment of the invention is depicted in
Also shown in
Also shown in
At least one of the communication lines between identifier 41 and device 42 is one in which the patient's body is employed as a fluid conduction medium. Other of the communication lines shown in
Of note in the embodiment shown in
Another embodiment of the invention that finds use for keeping track of when IV bags are attached to and delivered to a patient is described below in connection with
In this system, the transmitter capacitively couples a signal to the fluid. That signal transmits through the fluid and to the patient, through the patient's body, and to the receiver, specifically one electrode of the receiver (thereby making up one side of the conductive loop). The other side of the conductive loop includes the other side of the transmitter, which capacitively couples a signal to ground, i.e. everything surrounding a patient which is not attached to the patient. The ground may be chairs, tables, the floor, etc. The signal goes through the ground and then is capacitively coupled to the other side of the patch receiver, thereby completing the loop. This capacitive coupling on either side to ground is illustrated in the
Referring to
The fluid transfer signal may be a high frequency signal, e.g., between 1 and 10 MHz, and may be higher, e.g., 100 MHz or more, e.g., 1 GHz or more. The frequency is in a range such that the receiver only picks up the signal when the IV bag is connected to the body, and not just by the electromagnetic waves that are emitted by the broadcaster. In certain embodiments, the frequency is chosen based on the considerations that the higher the frequency, the easier it is to couple it directly to the IV bag, but the more likely it is that the signal will be picked up by the receiver regardless of whether the IV bag is connected to the body.
In certain embodiments, the fluid transfer signal also encodes a number, either through phase shift keying, or through frequency shift keying, or one of any other convenient telecommunications technique.
In a variation of the above embodiment, one may have multiple IV bags attached to the patient. Each of these IV bags has its own broadcaster, and each of them is encoded with a different encoded number. The IV bags may all be broadcasting on the same frequency, or they might be broadcasting on different frequencies, or in different frequency bands. Where desired, the systems can be time multiplexed or they can be frequency multiplexed. For example, the signals broadcast by the disparate components of a system may all be in the same frequency, and time multiplexing is employed (for example randomly associated), so that the disparate components are all broadcasting at least occasionally at a different point in time so that their signals can be distinguished from another.
By doing this, the receiver detects the signal from each of the IV bags, and knows when they are attached and when fluid is flowing from the bags into the patient. The system is configured, in certain embodiments, to determine when fluid is not flowing, or when it is interrupted. The system is configured, in certain embodiments, to measure the time and duration of infusion. As reviewed above, systems of the invention may be configured such that alarms are produced, whenever for example, the wrong bag is connected to the patient, or when the delivery is interrupted for any reason and fluid is no longer dripping through, or when a patient takes some other type of medication which would not be compatible with the medications delivered by the IV bag. The above discussion provides an example of a system configured to detect an error event and provide a reporting signal of the same. As such, the receiver may not only be measuring the medications delivered by the IV bag, but it may also be detecting when a person takes a pill, or breathes fluid from an inhaler, or is being dialyzed through a dialysis machine for kidney function, or for any of the other purposes where medical therapeutic elements are being administered to the patient.
In certain embodiments, the IV bag sets will have a drip carrier where the fluid drips from one point to another, e.g., as illustrated in
Alternatively, as shown in
Alternatively, one or more of the components of the IV system may be fabricated from conductive materials, e.g., drip bag component 59D, such as conductive plastics, that provide for the conductive link between the patient associated identifier 53 and the disparate components of the IV or other delivery system. In these embodiments, establishment of a fluid connection between the body and the fluid delivery device can work with or without liquids in the lines. As such, the system could be employed for O2 lines. In such embodiments, the entire system can be electronically checked for all connections made to a patient, not just those for medications, but also feeding, urinary and gaseous tubes, as well.
In certain embodiments, the IV bag is filled with a first fluid, such as saline. A nurse or other health practitioner injects a medicine into the IV bag, and then that combination is administered to the patient. In this situation, the vial containing the injected medicine is configured to transfer a signal to the syringe, and the syringe is configured to receive and record the signal, such that the syringe is receiver enabled itself. The syringe then broadcasts the signal to the IV bag, the IV bag receives the signal, and modifies the code it will broadcast to the patient associated identifier based on what was delivered and injected into the bag by the syringe. The signal broadcast to the patient associated identifier would thus be a different number that would reflect this additional medication.
Another variation of this system is where there are two separate links. One of multiple IV bags going into a fluid processing unit, e.g., pump, which may be a combining pump, and then a separate link between the processing unit and the patient. Referring to
Still referring to
Where desired, the external processor 68 can provide various alerts. For example, an IV bag may have bar codes on it for shipping and receiving purposes, and also for providing information to be transferred before the contents of the bag are administered to the patient. For example, a given medical fluid container with fluid may be bar coded and entered into the HIS. The prescription for a given patient with respect to that medical fluid container may also be entered into the HIS, and that prescription may be downloaded into the patient's patient associated identifier, e.g., through an RF link. In addition, the same information may be downloaded, for example to the IV pump that is being used to deliver the fluid inside the container to the patient.
The IV pump only permits delivery after two confirmations occur. First, the pump confirms with the patient associated identifier that the correct medication is going to be administered to the patient, as determined by the bar code and the patient associate identifier. After transmitting through the conductive link to the patient that this is the correct fluid, the system continues to allow a full delivery of fluid. For example, in the initial setup the IV pump fluid is primed and is introduced to the patient long enough for the conductive signal to be transmitted from the IV bag to the patient associated identifier. The patient associated identifier then responds by confirming that the fluid is being delivered, and confirming that the fluid being delivered is the right fluid. The system then continues to deliver the fluid to the patient. If, however, the system detects during this step that the fluid is not the right fluid, the pump is alerted to stop pumping. This is an example of a double confirmation system embodiment of the invention. The advantage of this type of embodiment is if there is an RFID tag or a bar code system on the bag and the bag is brought to the patient's room, one can know the bag is in the room, but will not know that the bag is being attached to the patient or delivered to the correct patient, instead of the fluid being delivered to the patient next door or simply sitting in the room and not attached to anybody. The RFID and the barcodes are a way to keep track of this product between the factory and the patient, and the transconduction link of the present invention confirms the delivery of the medication to this patient and not to some generic patient or the drain. Another use of the system is to prevent fraud, where the systems of the invention may be employed to make sure that medications are actually being delivered to patients and not discarded.
In certain embodiments the receiver includes physiologic sensors that are also making measurements of a patient's health status, e.g., heart rate, breathing rate, temperature, activity level. If the sensors detect something that is not expected, or dangerous, the system is configured, in certain embodiments, to send an alert (such as an error signal) through a convenient communications link, such as an RF link, to the network or relay station and through the information server system through the nurse's station. In some embodiments, it may also shut down the pump. For example, if the pump is delivering a pain medication, and the breathing rate starts to go lower than it should, the pump might be automatically shut down. In certain embodiments, the system could further include a type of medication that reverses the action of a pain medication, such as enabling the restarting of the person's heart if it stopped. Alternatively, there may be a defibrillator patch that is always applied to a patient, so just in case too much medicine is delivered, the system can automatically deliver a defibrillation signal that would restart a patient's heart if necessary. Other measures could also be provided. For example, the medication that is causing the trouble could be stopped. Other medications that could theoretically counteract the adverse reaction, e.g., restart the heart such as adrenaline may be administered, for example a small drip of adrenaline could be automatically started. This might be useful in places where there are a lot of patients, but not a lot of nurses or other medical practitioners to keep track of them.
In other embodiments, the receiver can activate an alert when the signal is successfully detected and decoded. This configuration provides the healthcare provider and/or patient with an indication that the medication and therapy monitoring system is working properly.
Other possible methods for indicating that the signal has been received include an audible sound, such as a beep, or a vibration. The receiver can optionally send an RF signal to a personal data assistant or other external device alerting the nurse that the drug delivery signal was successfully received by the receiver.
In some embodiments, an indicator which would only be detectable by the patient may be used. For example, in the case of a receiver in the form of an implantable unit or external skin patch, a piezoelectric vibration may occur when the signal is successfully received. Alternatively, an electrical stimulation can be administered, causing a tingling feeling in the patient.
The above description of error monitoring is not limited to IV parenteral delivery devices, but is also applicable to inhalers, pills, pumps, dialysis machines, and other parenteral delivery devices. The same system could also be used for a dialysis system, where instead of an infusion pump, the external device is a dialysis machine, e.g., as depicted in
Referring to
In that configuration, the current flow is between the IV bag 54 (or pump if included) and the fluid, and the fluid goes into the person's body. On the opposite side of the pump is a wire which would go to the article of clothing, or a bracelet or some other embodiment of the second conductor. That becomes the current loop path which is then picked up by the body and patient associated identifier associated therewith. The article of clothing could be something like a garment that the patient is always wearing in the hospital that has some sort of electric threads in it, and that is essentially a ground loop that goes around the person's body. That configuration provides the capacitive coupling to the skin, and provides sufficient differential current that the patient associated identifier picks up the signal. Alternatively, it could be part of the bed, where one could have a conductor in the bed, and every bed has some electrified element, so whenever one has the IV pump, one would clamp to the bed frame, and the bed frame becomes the conductor.
In certain embodiments, such as that shown in
In certain embodiments, the broadcasters are powered by coils arranged in various formats. In certain embodiments one may have two coils-one on the transmitter on the bag and one on the infusion pump, and energy is wirelessly sent from the pump to the transmitter on the bag to power the bag transmitter. In a variation of this embodiment, the coil for the bag transmitter is a detachable part that is attached to the infusion pump via a cord and placed adjacent to the IV bag. For convenience, there may be a pouch on the IV bag to hold the coil, the coil may be adhered to the bag, e.g., with fabric hook-and-loop attachment elements (e.g. VELCRO™), or the IV bag may be placed into a pouch that incorporates the coil into it. This embodiment is shown in
In yet another variation, shown in
These features may include the fabric hook-and-loop attachment elements, a pouch on the side of the bag, or a sleeve incorporating the transmitter into which the bag is placed. The transmitter continues to transmit an ID through the IV drip to the body mounted receiver using capacitively coupled signals. Alternatively, the capacitive plate might be incorporated into the IV bag construction and a connector provided to attach the reusable transmitter.
In another embodiment of the smart parenteral delivery system, the encoded information can also be linked to an internet system. For example, not only does the patient's receive system pick up the information, but by using, for example a wireless technology standard for exchanging data over short distances (e.g. BLUETOOTH™ wireless communication protocol), the encoded information can be broadcasted in a hospital bedside monitor.
The bedside monitor relays the information to the internet and subsequently to the data base management system. As such, the patient's medical record is immediately updated and could be verified against the patient's health record so that if the administered medicine was incorrect, e.g., not prescribed, then an alert is notified and either a nursing staff member or if necessary some other staff member is notified to take action. In some instances it could be a life threatening issue and this could act as an alert process before any serious injuries occur.
In an additional embodiment of the present invention, the type of medication, amount, and time of use can be detected in an inhaler. Located on the inhaler are two electrodes that are placed above and below the mouth.
In one embodiment of the present invention, medicine can be delivered only when the patient is inhaling. Typically, the injected medicine is to be inhaled in a stream of air to insure that delivered gas ends up in the patient's lungs. The present invention can detect the patient's air stream. When the air stream is detected, the inhaler delivers the medicine.
In one embodiment of the present invention, there is a differential pressure sensor to detect whether the patient is inhaling when the medicine is injected. The delivery of the medicine can be timed to when the patient is inhaling, so that when the patient is inhaling properly the medicine is delivered. After delivery of the medicine, a signal that encodes the type of medicine and date of use is broadcasted through the contacts on the inhaler. The signal is picked up by the receiver located in, on, or around the patient.
In another embodiment of the present invention, other types of cues can be used to indicate whether the patient successfully administered the medicine. For example, an impedance measurement between the mouth and inhaler indicates whether there is proper contact between the mouth and the inhaler. If the patient does not have a proper seal in the mouth, then the medicine is not delivered.
If the medicine is not successfully administered, the receiver either does not transmit any code, or a code is transmitted that indicates no medicine was delivered, e.g., the patient tried but failed to inject the medicine. In this way, the doctor or appropriate staff member could determine whether the medicine was administered properly and take action to illustrate proper procedure in taking the medicine.
In an additional embodiment of the present invention, the amount of medicine injected by the inhaler can be quantified. For example, one of the bits of transferred information can represent how much medicine is delivered. The amount of medicine delivered can be measured in a number of ways. For example, pressure sensors can measure the volume of medicine remaining. In another example, an electronic valve can deliver a set amount of medicine while a counter keeps track of the number of times the valve is opened.
In another embodiment of the present invention, the inhaler can provide feedback to the patient to alert whether or not the medicine has been administered. For example, the inhaler can produce a visual or audio alert when the medicine has been properly administered.
In an additional embodiment, the smart parenteral delivery system can be extended to detect when dialysis is being performed and how the dialysis is being performed, e.g., in a kidney patient. Hemodialysis systems typically use two tubes with needles in the body of the patient. One tube removes blood from the patient and carries it to the dialyzer to be filtered, after which it is injected back into the patient through the other tube.
One or both of the needles in contact with the patient can be used as transmit electrodes to send a signal when dialysis is being performed. Using both needles to transmit, one will be the relative anode, while the other is the relative cathode. Each needle would cycle between anode and cathode, since it is an AC system. When dialysis is being performed, a signal can be transmitted which has a code specific to dialysis systems. This code can be detected and decoded by a receiver located in, on, or around the patient. The receiver can keep track of when dialysis is performed, how long it was performed for, and what settings were selected on the dialysis machine, such as flow rate.
A wealth of additional information can also be transmitted to the receiver during dialysis. For example, the flow rate of the blood coming out of the patient, and the flow rate of the filtered blood going back in to the patient can be measured and transmitted. The receiver can then monitor if there is a misbalance of fluid going in and out of the patient, and set off an alarm if that is detected.
The pressure at each location can be measured, thus giving an indication of the pressure drop. The pressures can be used to determine whether a vein is collapsing, which can be a serious problem for dialysis. The pressure at the receiver location can also be measured, and compared to the pressures at each needle to give a pressure drop. In some embodiments, if the measured pressure drop indicates that a vein is collapsing, the system can signal the dialysis machine to slow the flow rate or shut down completely to wait for the veins to open up. In some embodiments, the system may activate an alert that would notify the nurse or other healthcare provider of the problem.
Other parameters that may be measured in the blood going into and out of the patient include, but are not limited to, temperature, oxygenation levels, hematocrit, and conductivity. The conductivity can be an indication of how effective the dialysis treatment is. A broad array of chemical analyses can also be performed on the blood going into and out of the patient. Examples of measurements that can be taken include the levels of calcium, potassium, and creatinine present in the blood. All of this information can be sent to the receiver.
Information about the dialyzer used to perform the treatment, such as the make, model, and serial number of the dialyzer can also be transmitted. Some patients may not always receive dialysis treatments at the same location or with the same machine. If a problem comes up, it may be helpful to know the specific machine that has been used for each dialysis treatment, to see if there is a correlation.
In some embodiments, the parameter measurement and data transmission can be integrated into the dialysis machine itself.
In other embodiments, an add-on module can be utilized to provide the added functionality. In some such embodiments, the add-on module can open up, and the two dialysis tubes can be placed across it. Upon closing the module, a needle will puncture one or both tubes, allowing the blood to be sampled for analysis. The module can then perform a variety of analyses on the blood going into and out of the patient, as well as the difference between the two, as discussed above. The same needles can be used to transmit the data. The differential signal can be transmitted through the tubes and then through the body. The two tubes go to different locations in the body, providing a signal which can be easily picked up by the receiver.
In other embodiments, the smart therapeutics system can be incorporated into a peritoneal dialysis system, in which dialysis solution (dialysate) is placed into the body for a period of time to absorb waste products, then drained and discarded.
In some embodiments, the data measured by the smart dialysis system can be continuously transmitted to the receiver. In other embodiments, the data can be transmitted at select intervals, or at the beginning and/or end of the dialysis treatment.
For patients with kidney failure, in which dialysis is performed several times per week, the record that the dialysis was performed, and the data obtained during the procedure, can be very valuable to the physician.
Once the transmitted information is detected by the receiver, it becomes part of the patient's record along with the other information, such as medications the patient has received through swallowing a pill, an IV, a syringe, an inhaler, or other means. All of the data can be provided to the physician when uploaded from the receiver. This allows for any healthcare provider to have access to the patient's detailed medical records and a log of recorded treatments.
Core 909 from
Since both the transmitter and receiver reference earth ground, there is a signal transmission loop present when the IV is attached to the patient and IV fluid is flowing. When the IV tube is attached to the patient, the signal is transmitted from the IV bag, down the tube, and picked up by the receiver located in or attached to the surface of the patient.
Oscillator 931 is shown in more detail in
There are many other techniques, which would be obvious to one skilled in the art, that can be used to handle multiple transmitters broadcasting simultaneously, as well as to clean up the signal and improve signal integrity. For example, a spread spectrum design can be used which utilizes many frequencies and adds some noise cancellation.
Oscillator 943 can be the same oscillator as discussed in U.S. Provisional Patent Application 60/829,832, entitled “In-Vivo Low Voltage Oscillator,” hereby incorporated by reference in its entirety. The basic functional blocks of the oscillator are shown in
Cycle counter block 935 from
The control circuit which controls the broadcast signal at the capacitors is shown in
When broadcasting is enabled, at every clock or every cycle the drives 979 and 981 are switching polarity and broadcasting the signal. This embodiment uses phase shift keying, so the polarity is switched using phase input 983 to encode different bits in the signal. Logic diagram 985 shows how the circuit operates for each broadcast input 977 and phase input 983. Other communication techniques, such as frequency shift keying, can be used in other embodiments.
This circuit can operate at about 20 kHz to about 1 GHz, such as about 100 kHz to about 20 MHz, and including about 200 kHz to about 1 MHz. The system can utilize multiple frequencies, a spread spectrum design, or a myriad of other techniques which are well known in the art in order to successfully transmit and receive the signal in a noisy environment. The circuit shown here is merely a simple example, and other layers of complexity to make the system more robust can be added.
A more detailed view of pads circuit 1015 is shown in
The active rectifier is shown in
A more detailed view of active diode highs 1023 and 1024 is shown in
The comparator 1045 from
Clock generator block 1055 is shown in more detail in
In other embodiments, the IV circuitry can be configured to measure and transmit the volume of fluid in the IV bag, which can give an indication of flow rate when multiple data points are gathered over a given time. In this embodiment, two capacitor plates are stuck or otherwise attached to the IV bag, with a third ground plate electrically attached to earth ground. The two capacitor plates attached to the IV bag do not need to be parallel and can be in a variety of shapes and orientations. The capacitance measured between the two plates attached to the IV bag will vary depending on the amount of fluid in the bag. When there is a lot of fluid in the IV bag between the two capacitor plates, the capacitance will be higher than when the fluid drains out of the IV bag, and there is more air between the plates. By looking at the change in capacitance over time, one can get an indication of the flow rate of medication from the IV bag.
With flexible IV bags, the capacitance measured may not vary linearly with the amount of fluid in the IV bag. For some applications, it may not be important to have a high level of accuracy, so this is acceptable. In other embodiments, the signal can be post linearized with look-up tables. If the typical capacitance versus fluid volume curve for a particular IV bag is known, this information can be used to make the calculated flow rates more accurate. In some embodiments, a certain number of points from the capacitance versus fluid volume curve that is characteristic of the type of bag being used can be transmitted along with the address. In other embodiments, modifications can be made to the IV bag or the shape of the capacitor plates in order to make the capacitance versus fluid volume curve more linear. For example, if the walls of the IV bag are made more rigid such that it does not change shape while the IV fluid is flowing, that will make the curve more linear.
In some embodiments, the chip can be programmed to broadcast the identifier address through the capacitor plates which are attached to the IV bag. After broadcasting the address for some predetermined number of pulses, the broadcaster goes quiet. During this time, the voltage between the two IV bag capacitor plates is ramped up and then discharged when it reaches a threshold. The voltage is ramped up a predetermined number of times, and these cycles are counted. After the voltage has been ramped up and discharged a certain number of times, another broadcast period follows. The time which passes between signal broadcasts will vary with capacitance. When the IV bag contains more fluid, the capacitance will be higher, and the time between signal broadcasts will be longer. As the IV bag drains, the capacitance will go down, and the time between signal broadcasts will get shorter. By counting the oscillator cycles during the ramp up period, the time between broadcasts can be measured, and the change can be monitored to give an indication of flow rate.
In other embodiments, other schemes to measure the change in capacitance can be used.
A more detailed view of chip 1101 is shown in
Pads circuit 1113 is shown in more detail in
There is an independent drive 1123 to short output B 1115 to ground. The transistor is relatively large, which provides a quick discharge. There is a small delay once the voltage passes the threshold during ramp up before the capacitor is discharged. There is also a slight delay at the lower voltage before the next ramp up. This creates a discontinuity when calculating the change in capacitance over time, but can be compensated for in the calculation.
Core circuit 1111 from
The control block is shown in more detail in
A simple implementation of a receiver which monitors multiple frequencies and picks up the signal sent by the IV bag broadcaster is depicted in
The circuit in
As indicated above, the systems and methods of the invention find use in a variety of different applications, which applications may be categorized as prospective applications, real-time applications and historical applications.
In certain embodiments of the invention, all medication orders are provided in a HIS. Patients in the hospital wear a patient associated identifier that is continuously updated, e.g., via a wireless link, with their personal updated medication orders. During fluid delivery, an IV pump only delivers medication to the patient after confirmation between the delivery device and patient associated identifier. Alerts may be distributed for situations where confirmation is not obtained. Furthermore, confirmation may be required for drug delivery to occur, and drug deliver may be inhibited in the absence of confirmation.
Also provided are kits for practicing the subject methods. Kits may include one or more receivers of the invention, as described above. In addition, the kits may include one or more parenteral dosage devices, e.g., preloaded syringes, vials, IV bags, etc. The dosage amount of the one or more pharmacological agents provided in a kit may be sufficient for a single application or for multiple applications. In certain embodiments, the kits may include a smart parenteral delivery system that provides specific identification and detection of parenteral beneficial agents or beneficial agents taken into the body through other methods, for example, through the use of a syringe, inhaler, or other device that administers medicine, such as described above.
The subject kits may also include instructions for how to practice the subject methods using the components of the kit. The instructions may be recorded on a suitable recording medium or substrate. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
Some or all components of the subject kits may be packaged in suitable packaging to maintain sterility. In many embodiments of the subject kits, the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the sterility of some or all of the components of the kit.
It is to be understood that this invention is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present invention is embodied by the appended claims.
This application is a continuation application of PCT application serial no. PCT/US2007/15547 designating the United States and filed on Jul. 6, 2007; which application pursuant to 35 U.S.C. §119 (e), claims priority to the filing date of: U.S. Provisional Patent Application Ser. No. 60/819,750 filed Jul. 7, 2006; U.S. Provisional Patent Application Ser. No. 60/891,883 filed Feb. 27, 2007; U.S. Provisional Patent Application Ser. No. 60/940,631 filed May 29, 2007; and U.S. Provisional Patent Application Ser. No. 60/946,706 filed Jun. 27, 2007; the disclosures of which applications are herein incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3812854 | Michaels et al. | May 1974 | A |
| 3880146 | Everett et al. | Apr 1975 | A |
| 4403989 | Christensen et al. | Sep 1983 | A |
| 4475905 | Himmelstrup | Oct 1984 | A |
| 4487602 | Christensen et al. | Dec 1984 | A |
| 4529401 | Leslie et al. | Jul 1985 | A |
| 4533346 | Cosgrove et al. | Aug 1985 | A |
| 4551133 | Zegers de Beyl et al. | Nov 1985 | A |
| 4621644 | Ellers | Nov 1986 | A |
| 4669479 | Dunseath, Jr. | Jun 1987 | A |
| 4705503 | Dorman et al. | Nov 1987 | A |
| 4795429 | Feldstein | Jan 1989 | A |
| 4850967 | Cosmai | Jul 1989 | A |
| 4911916 | Cleary | Mar 1990 | A |
| 4922901 | Brooks et al. | May 1990 | A |
| 5006342 | Cleary et al. | Apr 1991 | A |
| 5125888 | Howard et al. | Jun 1992 | A |
| 5135479 | Sibalis et al. | Aug 1992 | A |
| 5156911 | Stewart | Oct 1992 | A |
| 5167649 | Zook | Dec 1992 | A |
| 5190522 | Wojcicki et al. | Mar 1993 | A |
| 5205292 | Czar et al. | Apr 1993 | A |
| 5213568 | Lattin et al. | May 1993 | A |
| 5224927 | Tapper | Jul 1993 | A |
| 5246418 | Haynes et al. | Sep 1993 | A |
| 5284133 | Burns et al. | Feb 1994 | A |
| 5289824 | Mills et al. | Mar 1994 | A |
| 5300299 | Sweet et al. | Apr 1994 | A |
| 5317506 | Coutre et al. | May 1994 | A |
| 5331953 | Andersson et al. | Jul 1994 | A |
| 5351695 | Mills et al. | Oct 1994 | A |
| 5363842 | Mishelevich et al. | Nov 1994 | A |
| 5364838 | Rubsamen | Nov 1994 | A |
| 5394866 | Ritson et al. | Mar 1995 | A |
| 5404871 | Goodman et al. | Apr 1995 | A |
| 5415866 | Zook | May 1995 | A |
| 5423750 | Spiller | Jun 1995 | A |
| 5479920 | Piper et al. | Jan 1996 | A |
| 5487378 | Robertson et al. | Jan 1996 | A |
| 5505195 | Wolf | Apr 1996 | A |
| 5505958 | Bello et al. | Apr 1996 | A |
| 5507277 | Rubsamen et al. | Apr 1996 | A |
| 5509404 | Lloyd et al. | Apr 1996 | A |
| 5522378 | Ritson et al. | Jun 1996 | A |
| 5527288 | Gross et al. | Jun 1996 | A |
| 5536503 | Kitchell et al. | Jul 1996 | A |
| 5540669 | Sage, Jr. et al. | Jul 1996 | A |
| 5542410 | Goodman et al. | Aug 1996 | A |
| 5556421 | Prutchi et al. | Sep 1996 | A |
| 5570682 | Johnson | Nov 1996 | A |
| 5586550 | Ivri et al. | Dec 1996 | A |
| 5587237 | Korpman | Dec 1996 | A |
| 5593390 | Castellano et al. | Jan 1997 | A |
| RE35474 | Woodard et al. | Mar 1997 | E |
| 5608647 | Rubsamen et al. | Mar 1997 | A |
| 5616124 | Hague et al. | Apr 1997 | A |
| 5622162 | Johansson et al. | Apr 1997 | A |
| 5622180 | Tammi et al. | Apr 1997 | A |
| 5634899 | Shapland et al. | Jun 1997 | A |
| 5645855 | Lorenz | Jul 1997 | A |
| 5655516 | Goodman et al. | Aug 1997 | A |
| 5655523 | Hodson et al. | Aug 1997 | A |
| 5656286 | Miranda et al. | Aug 1997 | A |
| 5666945 | Davenport | Sep 1997 | A |
| 5676129 | Rocci, Jr. et al. | Oct 1997 | A |
| 5686099 | Sablotsky et al. | Nov 1997 | A |
| 5688232 | Flower | Nov 1997 | A |
| 5694919 | Rubsamen et al. | Dec 1997 | A |
| 5694920 | Abrams et al. | Dec 1997 | A |
| 5697899 | Hillman et al. | Dec 1997 | A |
| 5709202 | Lloyd et al. | Jan 1998 | A |
| 5713349 | Keaney | Feb 1998 | A |
| 5724986 | Jones, Jr. et al. | Mar 1998 | A |
| 5740793 | Hodson et al. | Apr 1998 | A |
| 5746711 | Sibalis et al. | May 1998 | A |
| 5781442 | Engleson et al. | Jul 1998 | A |
| 5794612 | Wachter et al. | Aug 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5809997 | Wolf | Sep 1998 | A |
| 5810888 | Fenn | Sep 1998 | A |
| 5813397 | Goodman et al. | Sep 1998 | A |
| 5823179 | Grychowski et al. | Oct 1998 | A |
| 5826570 | Goodman et al. | Oct 1998 | A |
| 5830175 | Flower | Nov 1998 | A |
| 5839430 | Cama | Nov 1998 | A |
| 5843014 | Lattin et al. | Dec 1998 | A |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851197 | Marano et al. | Dec 1998 | A |
| 5857994 | Flower | Jan 1999 | A |
| 5860957 | Jacobsen et al. | Jan 1999 | A |
| 5865786 | Sibalis et al. | Feb 1999 | A |
| 5865787 | Shapland et al. | Feb 1999 | A |
| 5873835 | Hastings et al. | Feb 1999 | A |
| 5894841 | Voges | Apr 1999 | A |
| 5906579 | Vander Salm et al. | May 1999 | A |
| 5906597 | McPhee | May 1999 | A |
| 5921237 | Eisele et al. | Jul 1999 | A |
| 5924997 | Campbell | Jul 1999 | A |
| 5925021 | Castellano et al. | Jul 1999 | A |
| 5928201 | Poulsen et al. | Jul 1999 | A |
| 5960792 | Lloyd et al. | Oct 1999 | A |
| 5967986 | Cimochowski et al. | Oct 1999 | A |
| 5967989 | Cimochowski et al. | Oct 1999 | A |
| 5991655 | Gross et al. | Nov 1999 | A |
| 5997501 | Gross et al. | Dec 1999 | A |
| 6006747 | Eisele et al. | Dec 1999 | A |
| 6012454 | Hodson et al. | Jan 2000 | A |
| 6018680 | Flower | Jan 2000 | A |
| 6024976 | Miranda et al. | Feb 2000 | A |
| 6029083 | Flower et al. | Feb 2000 | A |
| 6053873 | Govari et al. | Apr 2000 | A |
| 6053888 | Kong | Apr 2000 | A |
| 6055980 | Mecikalski et al. | May 2000 | A |
| RE36754 | Noel | Jun 2000 | E |
| 6076519 | Johnson | Jun 2000 | A |
| 6085740 | Ivri et al. | Jul 2000 | A |
| 6085742 | Wachter | Jul 2000 | A |
| 6095141 | Armer et al. | Aug 2000 | A |
| 6105571 | Coffee | Aug 2000 | A |
| 6109260 | Bathe | Aug 2000 | A |
| 6116233 | Denyer et al. | Sep 2000 | A |
| 6119684 | Nohl et al. | Sep 2000 | A |
| 6125844 | Samiotes | Oct 2000 | A |
| 6142146 | Abrams et al. | Nov 2000 | A |
| 6148815 | Wolf | Nov 2000 | A |
| 6152130 | Abrams et al. | Nov 2000 | A |
| 6196218 | Voges | Mar 2001 | B1 |
| 6196219 | Hess et al. | Mar 2001 | B1 |
| 6198966 | Heruth | Mar 2001 | B1 |
| 6202642 | McKinnon et al. | Mar 2001 | B1 |
| 6221383 | Miranda et al. | Apr 2001 | B1 |
| 6231560 | Bui et al. | May 2001 | B1 |
| 6237398 | Porat et al. | May 2001 | B1 |
| 6237589 | Denyer et al. | May 2001 | B1 |
| 6237594 | Davenport | May 2001 | B1 |
| 6245026 | Campbell et al. | Jun 2001 | B1 |
| 6251079 | Gambale et al. | Jun 2001 | B1 |
| 6254573 | Haim et al. | Jul 2001 | B1 |
| 6256533 | Yuzhakov et al. | Jul 2001 | B1 |
| 6260549 | Sosiak | Jul 2001 | B1 |
| 6269340 | Ford et al. | Jul 2001 | B1 |
| 6272370 | Gillies et al. | Aug 2001 | B1 |
| 6283951 | Flaherty et al. | Sep 2001 | B1 |
| 6283953 | Ayer et al. | Sep 2001 | B1 |
| 6309370 | Haim et al. | Oct 2001 | B1 |
| 6315719 | Rose et al. | Nov 2001 | B1 |
| 6316022 | Mantelle | Nov 2001 | B1 |
| 6318361 | Sosiak | Nov 2001 | B1 |
| 6327486 | Nissila et al. | Dec 2001 | B1 |
| 6340357 | Poulsen et al. | Jan 2002 | B1 |
| 6349724 | Burton et al. | Feb 2002 | B1 |
| 6352715 | Hwang et al. | Mar 2002 | B1 |
| 6377848 | Garde et al. | Apr 2002 | B1 |
| 6378520 | Davenport | Apr 2002 | B1 |
| 6385488 | Flower et al. | May 2002 | B1 |
| 6390088 | Nohl et al. | May 2002 | B1 |
| 6394997 | Lemelson | May 2002 | B1 |
| 6397838 | Zimlich et al. | Jun 2002 | B1 |
| 6406426 | Reuss et al. | Jun 2002 | B1 |
| 6413238 | Maget | Jul 2002 | B1 |
| 6422236 | Nilsson | Jul 2002 | B1 |
| 6425392 | Sosiak | Jul 2002 | B1 |
| 6427684 | Ritsche et al. | Aug 2002 | B2 |
| 6431171 | Burton | Aug 2002 | B1 |
| 6435175 | Stenzler | Aug 2002 | B1 |
| 6443146 | Voges | Sep 2002 | B1 |
| 6448303 | Paul | Sep 2002 | B1 |
| 6453195 | Thompson | Sep 2002 | B1 |
| 6468242 | Wilson et al. | Oct 2002 | B1 |
| 6484721 | Bliss | Nov 2002 | B1 |
| 6485461 | Mason et al. | Nov 2002 | B1 |
| 6516796 | Cox et al. | Feb 2003 | B1 |
| 6517481 | Hoek et al. | Feb 2003 | B2 |
| 6517527 | Gambale et al. | Feb 2003 | B2 |
| 6520928 | Junior et al. | Feb 2003 | B1 |
| 6527759 | Tachibana et al. | Mar 2003 | B1 |
| 6533733 | Ericson et al. | Mar 2003 | B1 |
| 6536423 | Conway | Mar 2003 | B2 |
| 6540154 | Ivri et al. | Apr 2003 | B1 |
| 6564093 | Ostrow et al. | May 2003 | B1 |
| 6568390 | Nichols et al. | May 2003 | B2 |
| 6575932 | O'Brien et al. | Jun 2003 | B1 |
| 6578741 | Ritsche et al. | Jun 2003 | B2 |
| 6582393 | Sage | Jun 2003 | B2 |
| 6584971 | Denyer et al. | Jul 2003 | B1 |
| 6585698 | Packman et al. | Jul 2003 | B1 |
| 6589229 | Connelly et al. | Jul 2003 | B1 |
| 6599281 | Struys et al. | Jul 2003 | B1 |
| 6605072 | Struys et al. | Aug 2003 | B2 |
| 6606989 | Brand et al. | Aug 2003 | B1 |
| 6607508 | Knauer | Aug 2003 | B2 |
| 6615827 | Greenwood et al. | Sep 2003 | B2 |
| 6629524 | Goodall et al. | Oct 2003 | B1 |
| 6640804 | Ivri et al. | Nov 2003 | B2 |
| 6651651 | Bonney et al. | Nov 2003 | B1 |
| 6655381 | Keane et al. | Dec 2003 | B2 |
| 6656148 | Das et al. | Dec 2003 | B2 |
| 6678555 | Flower et al. | Jan 2004 | B2 |
| 6685648 | Flaherty et al. | Feb 2004 | B2 |
| 6705316 | Blythe et al. | Mar 2004 | B2 |
| 6715487 | Nichols et al. | Apr 2004 | B2 |
| 6723077 | Pickup et al. | Apr 2004 | B2 |
| 6726661 | Munk et al. | Apr 2004 | B2 |
| 6728574 | Ujhelyi et al. | Apr 2004 | B2 |
| 6738662 | Frank | May 2004 | B1 |
| 6745761 | Christup et al. | Jun 2004 | B2 |
| 6745764 | Hickle | Jun 2004 | B2 |
| 6746429 | Sadowski et al. | Jun 2004 | B2 |
| 6748945 | Grychowski et al. | Jun 2004 | B2 |
| 6796305 | Banner et al. | Sep 2004 | B1 |
| 6796956 | Hartlaub et al. | Sep 2004 | B2 |
| 6807965 | Hickle | Oct 2004 | B1 |
| 6810290 | Lebel et al. | Oct 2004 | B2 |
| 6854461 | Nichols et al. | Feb 2005 | B2 |
| 6858011 | Sehgal | Feb 2005 | B2 |
| 6866037 | Aslin et al. | Mar 2005 | B1 |
| 6886557 | Childers et al. | May 2005 | B2 |
| 6893415 | Madsen et al. | May 2005 | B2 |
| 6902740 | Schaberg et al. | Jun 2005 | B2 |
| 6923784 | Stein et al. | Aug 2005 | B2 |
| 6941168 | Girouard et al. | Sep 2005 | B2 |
| 6949081 | Chance | Sep 2005 | B1 |
| 6958691 | Anderson et al. | Oct 2005 | B1 |
| 6961601 | Matthews et al. | Nov 2005 | B2 |
| 6971383 | Hickey et al. | Dec 2005 | B2 |
| 6981499 | Anderson et al. | Jan 2006 | B2 |
| 6983652 | Blakley et al. | Jan 2006 | B2 |
| 6985771 | Fischell et al. | Jan 2006 | B2 |
| 6985870 | Martucci et al. | Jan 2006 | B2 |
| 6990975 | Jones et al. | Jan 2006 | B1 |
| 6999854 | Roth | Feb 2006 | B2 |
| 7010337 | Furnary et al. | Mar 2006 | B2 |
| 7034692 | Hickle | Apr 2006 | B2 |
| 7040314 | Nguyen et al. | May 2006 | B2 |
| 7044911 | Drinan et al. | May 2006 | B2 |
| 7047964 | Bacon | May 2006 | B2 |
| 7054782 | Hartlaub | May 2006 | B2 |
| 7072802 | Hartlaub | Jul 2006 | B2 |
| 7089935 | Rand | Aug 2006 | B1 |
| 7097853 | Garbe et al. | Aug 2006 | B1 |
| 7104972 | Moller et al. | Sep 2006 | B2 |
| 7107988 | Pinon et al. | Sep 2006 | B2 |
| 7108680 | Rohr et al. | Sep 2006 | B2 |
| 7117867 | Cox et al. | Oct 2006 | B2 |
| 7138088 | Wariar et al. | Nov 2006 | B2 |
| 7147170 | Nguyen et al. | Dec 2006 | B2 |
| 7168597 | Jones et al. | Jan 2007 | B1 |
| 7181261 | Silver et al. | Feb 2007 | B2 |
| 7191777 | Brand et al. | Mar 2007 | B2 |
| 7198172 | Harvey et al. | Apr 2007 | B2 |
| 7201734 | Hickle | Apr 2007 | B2 |
| 7204823 | Estes et al. | Apr 2007 | B2 |
| 7220240 | Struys et al. | May 2007 | B2 |
| 7225805 | Bacon | Jun 2007 | B2 |
| 7232435 | Hildebrand et al. | Jun 2007 | B2 |
| 7242981 | Ginggen | Jul 2007 | B2 |
| 7247154 | Hickle | Jul 2007 | B2 |
| 7261733 | Brown et al. | Aug 2007 | B1 |
| 7267121 | Ivri et al. | Sep 2007 | B2 |
| 7278983 | Ireland et al. | Oct 2007 | B2 |
| 7291126 | Shekalim | Nov 2007 | B2 |
| 7320675 | Pastore et al. | Jan 2008 | B2 |
| 7322352 | Minshull et al. | Jan 2008 | B2 |
| 7322355 | Jones et al. | Jan 2008 | B2 |
| 7331340 | Barney | Feb 2008 | B2 |
| 7342660 | Altobelli et al. | Mar 2008 | B2 |
| 7347200 | Jones et al. | Mar 2008 | B2 |
| 7347202 | Aslin et al. | Mar 2008 | B2 |
| 7347851 | Kriksunov | Mar 2008 | B1 |
| 7367968 | Rosenberg et al. | May 2008 | B2 |
| 7380550 | Sexton et al. | Jun 2008 | B2 |
| 7382263 | Danowski et al. | Jun 2008 | B2 |
| 7383837 | Robertson et al. | Jun 2008 | B2 |
| 7387121 | Harvey | Jun 2008 | B2 |
| 7390311 | Hildebrand et al. | Jun 2008 | B2 |
| 7397730 | Skyggebjerg et al. | Jul 2008 | B2 |
| 7415384 | Hartlaub | Aug 2008 | B2 |
| 7424888 | Harvey et al. | Sep 2008 | B2 |
| 7455667 | Uhland et al. | Nov 2008 | B2 |
| 7458373 | Nichols et al. | Dec 2008 | B2 |
| 7467629 | Rand | Dec 2008 | B2 |
| 7483743 | Mann et al. | Jan 2009 | B2 |
| 7488305 | Mickley et al. | Feb 2009 | B2 |
| 7495546 | Lintell et al. | Feb 2009 | B2 |
| 7510551 | Uhland et al. | Mar 2009 | B2 |
| 7517332 | Tonelli et al. | Apr 2009 | B2 |
| 7520278 | Crowder et al. | Apr 2009 | B2 |
| 7530352 | Childers et al. | May 2009 | B2 |
| 7530975 | Hunter | May 2009 | B2 |
| 7537590 | Santini et al. | May 2009 | B2 |
| 7542798 | Girouard | Jun 2009 | B2 |
| 7544190 | Pickup et al. | Jun 2009 | B2 |
| 7548314 | Altobelli et al. | Jun 2009 | B2 |
| 7549421 | Levi et al. | Jun 2009 | B2 |
| 7552728 | Bonney et al. | Jun 2009 | B2 |
| 7554090 | Coleman et al. | Jun 2009 | B2 |
| 7575003 | Rasmusssen et al. | Aug 2009 | B2 |
| 7581540 | Hale et al. | Sep 2009 | B2 |
| 7597099 | Jones et al. | Oct 2009 | B2 |
| 7631643 | Morrison et al. | Dec 2009 | B2 |
| 7670329 | Flaherty et al. | Mar 2010 | B2 |
| 7672726 | Ginggen | Mar 2010 | B2 |
| 7677467 | Fink et al. | Mar 2010 | B2 |
| 7686788 | Freyman et al. | Mar 2010 | B2 |
| 7699060 | Bahm | Apr 2010 | B2 |
| 7699829 | Harris et al. | Apr 2010 | B2 |
| 7708011 | Hochrainer et al. | May 2010 | B2 |
| 7713229 | Veit et al. | May 2010 | B2 |
| 7715919 | Osorio et al. | May 2010 | B2 |
| 7717877 | Lavi et al. | May 2010 | B2 |
| 7725161 | Karmarkar et al. | May 2010 | B2 |
| 7783344 | Lackey et al. | Aug 2010 | B2 |
| 7904133 | Gehman et al. | Mar 2011 | B2 |
| 8016798 | Sparks et al. | Sep 2011 | B2 |
| 8162899 | Tennican | Apr 2012 | B2 |
| 8777894 | Butterfield | Jul 2014 | B2 |
| 20010000802 | Soykan et al. | May 2001 | A1 |
| 20010022279 | Denyer et al. | Sep 2001 | A1 |
| 20020000225 | Schuler et al. | Jan 2002 | A1 |
| 20020002349 | Flaherty et al. | Jan 2002 | A1 |
| 20020010432 | Klitmose et al. | Jan 2002 | A1 |
| 20020013615 | Haim et al. | Jan 2002 | A1 |
| 20020026940 | Brooker et al. | Mar 2002 | A1 |
| 20020077852 | Ford et al. | Jun 2002 | A1 |
| 20020099328 | Scheiner et al. | Jul 2002 | A1 |
| 20020120236 | Diaz et al. | Aug 2002 | A1 |
| 20020153006 | Zimlich et al. | Oct 2002 | A1 |
| 20020189612 | Rand et al. | Dec 2002 | A1 |
| 20020189615 | Henry et al. | Dec 2002 | A1 |
| 20020198493 | Diaz et al. | Dec 2002 | A1 |
| 20030004236 | Meade et al. | Jan 2003 | A1 |
| 20030078561 | Gambale et al. | Apr 2003 | A1 |
| 20030079744 | Bonney et al. | May 2003 | A1 |
| 20030094508 | Peng et al. | May 2003 | A1 |
| 20030136418 | Behm et al. | Jul 2003 | A1 |
| 20030140921 | Smith et al. | Jul 2003 | A1 |
| 20030150446 | Patel et al. | Aug 2003 | A1 |
| 20030159693 | Melker et al. | Aug 2003 | A1 |
| 20030168057 | Snyder et al. | Sep 2003 | A1 |
| 20030171738 | Konieczynski et al. | Sep 2003 | A1 |
| 20030176804 | Melker | Sep 2003 | A1 |
| 20030176808 | Masuo | Sep 2003 | A1 |
| 20030183226 | Brand et al. | Oct 2003 | A1 |
| 20030205229 | Crockford et al. | Nov 2003 | A1 |
| 20040004133 | Ivri et al. | Jan 2004 | A1 |
| 20040019321 | Sage et al. | Jan 2004 | A1 |
| 20040025871 | Davies et al. | Feb 2004 | A1 |
| 20040031331 | Blakley et al. | Feb 2004 | A1 |
| 20040050385 | Bonney et al. | Mar 2004 | A1 |
| 20040089299 | Bonney et al. | May 2004 | A1 |
| 20040098117 | Hossainy et al. | May 2004 | A1 |
| 20040106902 | Diaz et al. | Jun 2004 | A1 |
| 20040122530 | Hansen et al. | Jun 2004 | A1 |
| 20040133154 | Flaherty et al. | Jul 2004 | A1 |
| 20040139963 | Ivri et al. | Jul 2004 | A1 |
| 20040158167 | Smith et al. | Aug 2004 | A1 |
| 20040181196 | Pickup et al. | Sep 2004 | A1 |
| 20040187864 | Adams et al. | Sep 2004 | A1 |
| 20040193453 | Butterfield et al. | Sep 2004 | A1 |
| 20040210199 | Atterbury et al. | Oct 2004 | A1 |
| 20040254435 | Mathews et al. | Dec 2004 | A1 |
| 20050010166 | Hickle | Jan 2005 | A1 |
| 20050045734 | Peng et al. | Mar 2005 | A1 |
| 20050059924 | Katz et al. | Mar 2005 | A1 |
| 20050072421 | Suman et al. | Apr 2005 | A1 |
| 20050081845 | Barney et al. | Apr 2005 | A1 |
| 20050087189 | Crockford et al. | Apr 2005 | A1 |
| 20050137626 | Pastore et al. | Jun 2005 | A1 |
| 20050139651 | Lim et al. | Jun 2005 | A1 |
| 20050155602 | Lipp | Jul 2005 | A1 |
| 20050165342 | Odland | Jul 2005 | A1 |
| 20050171451 | Yeo et al. | Aug 2005 | A1 |
| 20050172956 | Childers et al. | Aug 2005 | A1 |
| 20050172958 | Singer et al. | Aug 2005 | A1 |
| 20050183725 | Gumaste et al. | Aug 2005 | A1 |
| 20050203637 | Edman et al. | Sep 2005 | A1 |
| 20050235732 | Rush | Oct 2005 | A1 |
| 20050236501 | Zimlich et al. | Oct 2005 | A1 |
| 20050245906 | Makower et al. | Nov 2005 | A1 |
| 20050247312 | Davies | Nov 2005 | A1 |
| 20050251289 | Bonney et al. | Nov 2005 | A1 |
| 20050274378 | Bonney et al. | Dec 2005 | A1 |
| 20060005842 | Rashad et al. | Jan 2006 | A1 |
| 20060030813 | Chance | Feb 2006 | A1 |
| 20060031099 | Vitello et al. | Feb 2006 | A1 |
| 20060037612 | Herder et al. | Feb 2006 | A1 |
| 20060042632 | Bishop et al. | Mar 2006 | A1 |
| 20060058593 | Drinan et al. | Mar 2006 | A1 |
| 20060090752 | Imondi et al. | May 2006 | A1 |
| 20060130832 | Schechter et al. | Jun 2006 | A1 |
| 20060131350 | Schechter et al. | Jun 2006 | A1 |
| 20060167530 | Flaherty et al. | Jul 2006 | A1 |
| 20060178586 | Dobak | Aug 2006 | A1 |
| 20060184087 | Wariar et al. | Aug 2006 | A1 |
| 20060191534 | Hickey et al. | Aug 2006 | A1 |
| 20060201499 | Muellinger et al. | Sep 2006 | A1 |
| 20060204532 | John et al. | Sep 2006 | A1 |
| 20060231093 | Burge et al. | Oct 2006 | A1 |
| 20060243277 | Denyer et al. | Nov 2006 | A1 |
| 20060253005 | Drinan | Nov 2006 | A1 |
| 20060283465 | Nickel | Dec 2006 | A1 |
| 20070023034 | Jongejan et al. | Feb 2007 | A1 |
| 20070023036 | Grychowski et al. | Feb 2007 | A1 |
| 20070043591 | Meretei et al. | Feb 2007 | A1 |
| 20070044793 | Kleinstreuer et al. | Mar 2007 | A1 |
| 20070060800 | Drinan et al. | Mar 2007 | A1 |
| 20070074722 | Giroux et al. | Apr 2007 | A1 |
| 20070088334 | Hillis et al. | Apr 2007 | A1 |
| 20070091273 | Sullivan et al. | Apr 2007 | A1 |
| 20070107517 | Arnold et al. | May 2007 | A1 |
| 20070123829 | Atterbury et al. | May 2007 | A1 |
| 20070125370 | Denyer et al. | Jun 2007 | A1 |
| 20070157931 | Parker et al. | Jul 2007 | A1 |
| 20070161879 | Say et al. | Jul 2007 | A1 |
| 20070169778 | Smith et al. | Jul 2007 | A1 |
| 20070197954 | Keenan | Aug 2007 | A1 |
| 20070203411 | Say et al. | Aug 2007 | A1 |
| 20070208322 | Rantala et al. | Sep 2007 | A1 |
| 20070209659 | Ivri et al. | Sep 2007 | A1 |
| 20070213658 | Hickle | Sep 2007 | A1 |
| 20070221218 | Warden et al. | Sep 2007 | A1 |
| 20070224128 | Dennis et al. | Sep 2007 | A1 |
| 20070240712 | Fleming et al. | Oct 2007 | A1 |
| 20070256688 | Schuster et al. | Nov 2007 | A1 |
| 20070258894 | Melker et al. | Nov 2007 | A1 |
| 20070295329 | Lieberman et al. | Dec 2007 | A1 |
| 20070299550 | Nishijima et al. | Dec 2007 | A1 |
| 20080009800 | Nickel | Jan 2008 | A1 |
| 20080021379 | Hickle | Jan 2008 | A1 |
| 20080039700 | Drinan et al. | Feb 2008 | A1 |
| 20080051667 | Goldreich | Feb 2008 | A1 |
| 20080058703 | Subramony et al. | Mar 2008 | A1 |
| 20080077080 | Hengstenberg et al. | Mar 2008 | A1 |
| 20080078382 | LeMahieu et al. | Apr 2008 | A1 |
| 20080078385 | Xiao et al. | Apr 2008 | A1 |
| 20080082001 | Hatlestad et al. | Apr 2008 | A1 |
| 20080086112 | Lo et al. | Apr 2008 | A1 |
| 20080091138 | Pastore et al. | Apr 2008 | A1 |
| 20080114299 | Damgaard-Sorensen et al. | May 2008 | A1 |
| 20080125759 | Konieczynski et al. | May 2008 | A1 |
| 20080142002 | Fink et al. | Jun 2008 | A1 |
| 20080147004 | Mann et al. | Jun 2008 | A1 |
| 20080147050 | Mann et al. | Jun 2008 | A1 |
| 20080173301 | Deaton et al. | Jul 2008 | A1 |
| 20080177246 | Sullican et al. | Jul 2008 | A1 |
| 20080178872 | Genova et al. | Jul 2008 | A1 |
| 20080200804 | Hartlep et al. | Aug 2008 | A1 |
| 20080216834 | Easley et al. | Sep 2008 | A1 |
| 20080221408 | Hoarau et al. | Sep 2008 | A1 |
| 20080262469 | Brister et al. | Oct 2008 | A1 |
| 20080269689 | Edwards et al. | Oct 2008 | A1 |
| 20080281276 | Shekalim | Nov 2008 | A1 |
| 20080306436 | Edwards et al. | Dec 2008 | A1 |
| 20080306444 | Brister et al. | Dec 2008 | A1 |
| 20080306449 | Kristensen et al. | Dec 2008 | A1 |
| 20090005763 | Makower et al. | Jan 2009 | A1 |
| 20090024112 | Edwards et al. | Jan 2009 | A1 |
| 20090025714 | Denyer et al. | Jan 2009 | A1 |
| 20090025718 | Denyer et al. | Jan 2009 | A1 |
| 20090030285 | Andersen | Jan 2009 | A1 |
| 20090048526 | Aarts et al. | Feb 2009 | A1 |
| 20090048556 | Durand | Feb 2009 | A1 |
| 20090056708 | Stenzler et al. | Mar 2009 | A1 |
| 20090064997 | Li | Mar 2009 | A1 |
| 20090082829 | Panken et al. | Mar 2009 | A1 |
| 20090107503 | Baran | Apr 2009 | A1 |
| 20090151718 | Hunter et al. | Jun 2009 | A1 |
| 20090156952 | Hunter et al. | Jun 2009 | A1 |
| 20090163781 | Say et al. | Jun 2009 | A1 |
| 20090187167 | Sexton et al. | Jul 2009 | A1 |
| 20090194104 | Van Sickle | Aug 2009 | A1 |
| 20090211576 | Lehtonen et al. | Aug 2009 | A1 |
| 20090213373 | Altobelli et al. | Aug 2009 | A1 |
| 20090216194 | Elgard et al. | Aug 2009 | A1 |
| 20090221087 | Martin et al. | Sep 2009 | A1 |
| 20090227941 | Say et al. | Sep 2009 | A1 |
| 20090229607 | Brunnberg et al. | Sep 2009 | A1 |
| 20090241951 | Jafari et al. | Oct 2009 | A1 |
| 20090241955 | Jafari et al. | Oct 2009 | A1 |
| 20090270752 | Coifman | Oct 2009 | A1 |
| 20090301472 | Kim et al. | Dec 2009 | A1 |
| 20090314372 | Ruskewicz et al. | Dec 2009 | A1 |
| 20090326509 | Muse et al. | Dec 2009 | A1 |
| 20090326510 | Haefner et al. | Dec 2009 | A1 |
| 20100012120 | Herder et al. | Jan 2010 | A1 |
| 20100031957 | McIntosh et al. | Feb 2010 | A1 |
| 20100049004 | Edman et al. | Feb 2010 | A1 |
| 20100049172 | Chance | Feb 2010 | A1 |
| 20100078015 | Imran | Apr 2010 | A1 |
| 20100094099 | Levy et al. | Apr 2010 | A1 |
| 20100099967 | Say et al. | Apr 2010 | A1 |
| 20100100078 | Say et al. | Apr 2010 | A1 |
| 20100100160 | Edman et al. | Apr 2010 | A1 |
| 20100106098 | Atterbury et al. | Apr 2010 | A1 |
| 20100114026 | Karratt et al. | May 2010 | A1 |
| 20100114060 | Ginggen et al. | May 2010 | A1 |
| 20100116070 | Farina et al. | May 2010 | A1 |
| 20100121314 | Iobbi | May 2010 | A1 |
| 20100122697 | Przekwas et al. | May 2010 | A1 |
| 20100268111 | Drinan et al. | Oct 2010 | A1 |
| 20110224912 | Bhavaraju et al. | Sep 2011 | A1 |
| 20110230732 | Edman et al. | Sep 2011 | A1 |
| Number | Date | Country |
|---|---|---|
| 0329306 | Aug 1989 | EP |
| 2248461 | Nov 2010 | EP |
| 6296633 | Oct 1994 | JP |
| 2001-061799 | Mar 2001 | JP |
| 2008-525063 | Jul 2008 | JP |
| WO8102982 | Oct 1981 | WO |
| WO8607269 | Dec 1986 | WO |
| WO9207599 | May 1992 | WO |
| WO9209324 | Jun 1992 | WO |
| WO9211808 | Jul 1992 | WO |
| WO9215353 | Sep 1992 | WO |
| WO9217231 | Oct 1992 | WO |
| WO9306803 | Apr 1993 | WO |
| WO9312823 | Jul 1993 | WO |
| WO9405359 | Mar 1994 | WO |
| WO9408655 | Apr 1994 | WO |
| WO9416755 | Aug 1994 | WO |
| WO9416756 | Aug 1994 | WO |
| WO9416759 | Aug 1994 | WO |
| WO9427653 | Dec 1994 | WO |
| WO9507723 | Mar 1995 | WO |
| WO9507724 | Mar 1995 | WO |
| WO9513838 | May 1995 | WO |
| WO9526769 | Oct 1995 | WO |
| WO9610440 | Apr 1996 | WO |
| WO9616686 | Jun 1996 | WO |
| WO9625186 | Aug 1996 | WO |
| WO9625978 | Aug 1996 | WO |
| WO9627341 | Sep 1996 | WO |
| WO9630078 | Oct 1996 | WO |
| WO9707896 | Mar 1997 | WO |
| WO9711655 | Apr 1997 | WO |
| WO9711742 | Apr 1997 | WO |
| WO9711743 | Apr 1997 | WO |
| WO9726934 | Jul 1997 | WO |
| WO9733640 | Sep 1997 | WO |
| WO9733645 | Sep 1997 | WO |
| WO9748431 | Dec 1997 | WO |
| WO9800188 | Jan 1998 | WO |
| WO9801168 | Jan 1998 | WO |
| WO9806450 | Feb 1998 | WO |
| WO9814235 | Apr 1998 | WO |
| WO9832479 | Jul 1998 | WO |
| WO9839057 | Sep 1998 | WO |
| WO9844984 | Oct 1998 | WO |
| WO9850095 | Nov 1998 | WO |
| WO9900144 | Jan 1999 | WO |
| WO9930760 | Jun 1999 | WO |
| WO9965551 | Dec 1999 | WO |
| WO0001434 | Jan 2000 | WO |
| WO0007652 | Feb 2000 | WO |
| WO0018339 | Apr 2000 | WO |
| WO0021598 | Apr 2000 | WO |
| WO0027278 | May 2000 | WO |
| WO0032267 | Jun 2000 | WO |
| WO0038770 | Jul 2000 | WO |
| WO0043059 | Jul 2000 | WO |
| WO0047253 | Aug 2000 | WO |
| WO0050111 | Aug 2000 | WO |
| WO0053247 | Sep 2000 | WO |
| WO0059483 | Oct 2000 | WO |
| 0105463 | Jan 2001 | WO |
| WO0113973 | Mar 2001 | WO |
| WO0124851 | Apr 2001 | WO |
| WO0130419 | May 2001 | WO |
| WO0158236 | Aug 2001 | WO |
| WO0168169 | Sep 2001 | WO |
| WO0183007 | Nov 2001 | WO |
| WO0185027 | Nov 2001 | WO |
| WO0187378 | Nov 2001 | WO |
| WO0189607 | Nov 2001 | WO |
| WO0200280 | Jan 2002 | WO |
| WO0202052 | Jan 2002 | WO |
| WO0204043 | Jan 2002 | WO |
| WO0217988 | Mar 2002 | WO |
| WO0217998 | Mar 2002 | WO |
| WO0224257 | Mar 2002 | WO |
| WO0224268 | Mar 2002 | WO |
| WO0234318 | May 2002 | WO |
| WO0236181 | May 2002 | WO |
| WO02053223 | Jul 2002 | WO |
| WO02072178 | Sep 2002 | WO |
| WO02076533 | Oct 2002 | WO |
| WO02078535 | Oct 2002 | WO |
| WO02081016 | Oct 2002 | WO |
| WO02089879 | Nov 2002 | WO |
| WO02089884 | Nov 2002 | WO |
| WO02096489 | Dec 2002 | WO |
| WO03006091 | Jan 2003 | WO |
| WO03008014 | Jan 2003 | WO |
| WO03020349 | Mar 2003 | WO |
| WO03022327 | Mar 2003 | WO |
| WO03028797 | Apr 2003 | WO |
| WO03035172 | May 2003 | WO |
| WO03038566 | May 2003 | WO |
| WO03045302 | Jun 2003 | WO |
| WO03059413 | Jul 2003 | WO |
| WO03071930 | Sep 2003 | WO |
| WO03073977 | Sep 2003 | WO |
| WO03086505 | Oct 2003 | WO |
| WO03090821 | Nov 2003 | WO |
| WO03097120 | Nov 2003 | WO |
| WO2004009161 | Jan 2004 | WO |
| WO2004011067 | Feb 2004 | WO |
| WO2004012801 | Feb 2004 | WO |
| WO2004020024 | Mar 2004 | WO |
| WO2004021882 | Mar 2004 | WO |
| WO2004022128 | Mar 2004 | WO |
| WO2004022153 | Mar 2004 | WO |
| WO2004022242 | Mar 2004 | WO |
| WO2004026380 | Apr 2004 | WO |
| WO2004032989 | Apr 2004 | WO |
| WO2004034998 | Apr 2004 | WO |
| WO2004041334 | May 2004 | WO |
| WO2004041339 | May 2004 | WO |
| WO2004045690 | Jun 2004 | WO |
| WO2004060436 | Jul 2004 | WO |
| WO2004060443 | Jul 2004 | WO |
| WO2004060447 | Jul 2004 | WO |
| WO2004080522 | Sep 2004 | WO |
| WO2004088567 | Oct 2004 | WO |
| WO2005009514 | Feb 2005 | WO |
| WO2005011779 | Feb 2005 | WO |
| WO2005028008 | Mar 2005 | WO |
| WO2005031317 | Apr 2005 | WO |
| WO2005039750 | May 2005 | WO |
| WO2005046559 | May 2005 | WO |
| WO2005051177 | Jun 2005 | WO |
| WO2005072798 | Aug 2005 | WO |
| WO2005084275 | Sep 2005 | WO |
| WO2005084738 | Sep 2005 | WO |
| WO2005087299 | Sep 2005 | WO |
| WO2005102412 | Nov 2005 | WO |
| WO2005102417 | Nov 2005 | WO |
| WO2005102418 | Nov 2005 | WO |
| WO2005102428 | Nov 2005 | WO |
| WO2005120615 | Dec 2005 | WO |
| WO2005123002 | Dec 2005 | WO |
| WO2006003665 | Jan 2006 | WO |
| WO2006009596 | Jan 2006 | WO |
| WO2006015299 | Feb 2006 | WO |
| 2006029090 | Mar 2006 | WO |
| WO2006022714 | Mar 2006 | WO |
| WO2006023644 | Mar 2006 | WO |
| WO2006035443 | Apr 2006 | WO |
| WO2006044206 | Apr 2006 | WO |
| WO2006045524 | May 2006 | WO |
| 2006069323 | Jun 2006 | WO |
| WO2006058426 | Jun 2006 | WO |
| WO2006060106 | Jun 2006 | WO |
| WO2006079898 | Aug 2006 | WO |
| WO2006096286 | Sep 2006 | WO |
| WO2006098933 | Sep 2006 | WO |
| WO2006098936 | Sep 2006 | WO |
| WO2006113408 | Oct 2006 | WO |
| 2006116718 | Nov 2006 | WO |
| WO2006120253 | Nov 2006 | WO |
| WO2006124759 | Nov 2006 | WO |
| WO2006125577 | Nov 2006 | WO |
| WO2006127257 | Nov 2006 | WO |
| WO2006127905 | Nov 2006 | WO |
| WO2006127953 | Nov 2006 | WO |
| WO2006128794 | Dec 2006 | WO |
| WO2006130098 | Dec 2006 | WO |
| WO2006133101 | Dec 2006 | WO |
| WO2007012854 | Feb 2007 | WO |
| 2007028035 | Mar 2007 | WO |
| WO2007031740 | Mar 2007 | WO |
| WO2007034237 | Mar 2007 | WO |
| WO2007041158 | Apr 2007 | WO |
| WO2007041471 | Apr 2007 | WO |
| WO2007051563 | May 2007 | WO |
| WO2007070093 | Jun 2007 | WO |
| WO2007070695 | Jun 2007 | WO |
| 2007120884 | Oct 2007 | WO |
| WO2007125699 | Nov 2007 | WO |
| WO2007127981 | Nov 2007 | WO |
| WO2007131025 | Nov 2007 | WO |
| WO2008008281 | Jan 2008 | WO |
| WO2008016698 | Feb 2008 | WO |
| WO2008021252 | Feb 2008 | WO |
| WO2008022010 | Feb 2008 | WO |
| WO2008029403 | Mar 2008 | WO |
| WO2008030837 | Mar 2008 | WO |
| WO2008037801 | Apr 2008 | WO |
| WO2008038241 | Apr 2008 | WO |
| WO2008039091 | Apr 2008 | WO |
| WO2008043724 | Apr 2008 | WO |
| WO2008052039 | May 2008 | WO |
| WO2008073806 | Jun 2008 | WO |
| WO2008077706 | Jul 2008 | WO |
| WO2008078287 | Jul 2008 | WO |
| 2008095183 | Aug 2008 | WO |
| WO2008103620 | Aug 2008 | WO |
| WO2008115906 | Sep 2008 | WO |
| WO2008117226 | Oct 2008 | WO |
| WO2008127743 | Oct 2008 | WO |
| WO2008130801 | Oct 2008 | WO |
| WO2008134107 | Nov 2008 | WO |
| WO2008134545 | Nov 2008 | WO |
| WO2008152588 | Dec 2008 | WO |
| WO2008154312 | Dec 2008 | WO |
| WO2008154504 | Dec 2008 | WO |
| WO2009003989 | Jan 2009 | WO |
| WO2009008001 | Jan 2009 | WO |
| WO2009013501 | Jan 2009 | WO |
| WO2009013670 | Jan 2009 | WO |
| WO2009023247 | Feb 2009 | WO |
| WO2009035759 | Mar 2009 | WO |
| WO2009042379 | Apr 2009 | WO |
| WO2009049252 | Apr 2009 | WO |
| WO2009063421 | May 2009 | WO |
| WO2009072079 | Jun 2009 | WO |
| WO2009076363 | Jun 2009 | WO |
| WO2009079589 | Jun 2009 | WO |
| WO2009081262 | Jul 2009 | WO |
| WO2009091851 | Jul 2009 | WO |
| WO2009098648 | Aug 2009 | WO |
| WO2009105337 | Aug 2009 | WO |
| WO2009110702 | Sep 2009 | WO |
| WO2009126653 | Oct 2009 | WO |
| WO2009137661 | Nov 2009 | WO |
| WO2009140251 | Nov 2009 | WO |
| WO2009140360 | Nov 2009 | WO |
| WO2009145801 | Dec 2009 | WO |
| WO2009155335 | Dec 2009 | WO |
| WO2010007573 | Jan 2010 | WO |
| WO2010007574 | Jan 2010 | WO |
| WO2010008424 | Jan 2010 | WO |
| WO2010010473 | Jan 2010 | WO |
| WO2010021589 | Feb 2010 | WO |
| WO2010023591 | Mar 2010 | WO |
| WO2010025428 | Mar 2010 | WO |
| WO2010025431 | Mar 2010 | WO |
| WO2010029054 | Mar 2010 | WO |
| WO2010037828 | Apr 2010 | WO |
| WO2010042034 | Apr 2010 | WO |
| WO2010043054 | Apr 2010 | WO |
| WO2010045460 | Apr 2010 | WO |
| WO2010051551 | May 2010 | WO |
| WO2010052275 | May 2010 | WO |
| WO2010062675 | Jun 2010 | WO |
| Entry |
|---|
| Aade, “AADE 37th Annual Meeting San Antonio Aug. 4-7, 2010” American Association of Diabetes Educators (2010); http://www.diabeteseducator.org/annualmeeting/2010/index.html; 2 pp. |
| Juvenile Diabetes Research Foundation International (JDRF), “Artificial Pancreas Project” (2010); http://www.artificialpancreasproject.com/; 3 pp. |
| Lifescan, “OneTouch UltraLink™” http://www.lifescan.com/products/meters/ultralink (N.D.) 2 pp. |
| Medtronic, “CareLink Therapy Management Software for Diabetes” (2010); https://carelink.minimed.com/patient/entry.jsp?bhcp=1; 1 pp. |
| Medtronic, “Carelink™ USB” (n.d.) http://www.medtronicdiabetes.com/pdf/carelink—usb—factsheet.pdf 2pp. |
| Medtronic “The New MiniMed Paradigm® REAL-Time Revel™ System” http://www.medtronicdiabetes.com/products/index.html; 2 pp. |
| Medtronic, “MINI MED Paradigm ® Revel ™ Insulin Pump” (n.d.) http://www.medtronicdiabetes.com/products/insulinpumps/index.html; 2 pp. |
| Medtronic, Mini Med Paradigm™ Veo™ System: Factsheet (2010). http://www.medtronic-diabetes.com.au/downloads/Paradigm%20Veo%20Factsheet.pdf ; 4 pp. |
| Park, “Medtronic to Buy MiniMed for $3.7 Billion” (2001) HomeCare; http://homecaremag.com/mag/medical—medtronic—buy—minimed/; 2 pp. |
| Nikander et al., “The Adaptive Delivery System in a Telehealth Setting: Patient Acceptance, Performance and Feasibility” Journal of Aerosol Medicine and Pulmonary Drug Delivery; vol. 23, Supp. 1, (2010) pp. S21-S27. |
| Prutchi et al., “Design and Development of Medical Electronic Instrumentation: A Practical Perspective of the Design, Construction, and Test of Medical Devices” Wiley-Interscience (2005) pp. 12-14. |
| Number | Date | Country | |
|---|---|---|---|
| 20090118594 A1 | May 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60819750 | Jul 2006 | US | |
| 60891883 | Feb 2007 | US | |
| 60940631 | May 2007 | US | |
| 60946706 | Jun 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2007/015547 | Jul 2007 | US |
| Child | 12349453 | US |
